- Condition: Multiple Myeloma
Interventions: Drug: Placebo; Drug: Dexamethasone; Drug: Bortezomib; Biological: Tabalumab
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Not yet recruiting - verified May 2012 - Condition: Cataract
Interventions: Drug: 40 mg/mL Dexamethasone phosphate ophthalmic solution; Drug: 100 mM sodium citrate buffer solution
Sponsors: Eyegate Pharmaceuticals, Inc.; Eyegate Pharmaceuticals, Inc.
Not yet recruiting - verified May 2012 - Condition: Psoriasis
Interventions: Drug: 80 mg ixekizumab Dosing Regimen; Drug: 50 mg etanercept; Drug: Placebo
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Not yet recruiting - verified May 2012 - Condition: Metastatic Castration-resistant Prostate Cancer
Interventions: Drug: Cabazitaxel; Drug: Mitoxantrone; Drug: Prednisone; Drug: Pegfilgrastim
Sponsors: University of California, San Francisco; Andrea Harzstark; Sanofi-Aventis
Not yet recruiting - verified May 2012 - Condition: Impaired Glucose Tolerance
Interventions: Dietary Supplement: Resveratrol; Dietary Supplement: resveratrol /HMB; Other: Placebo treatment
Sponsors: Vanderbilt University; Vanderbilt University; Nutraceutical Discoveries, Inc.
Recruiting - verified May 2012 - Condition: Coronary Artery Disease
Interventions: Device: PROMUS Element Plus Coronary Stent System; Drug: Aspirin; Drug: P2Y12 antagonist
Sponsors: Boston Scientific Corporation; Boston Scientific Corporation
Not yet recruiting - verified May 2012 - Conditions: Asthma, Aspirin-Induced; Aspirin Exacerbated Asthma
Intervention: Drug: Prasugrel
Sponsors: Brigham and Women's Hospital; Elliot Israel, MD; Brigham and Women's Hospital
Not yet recruiting - verified May 2012 - Condition: Bioequivalence
Interventions: Drug: Flector patch; Device: Microdialysis probe
Sponsors: University of Florida; University of Florida; Food and Drug Administration (FDA)
Recruiting - verified May 2012 - Conditions: Tendinosis; Tendinitis
Interventions: Procedure: Tenotomy; Drug: Ultrasound guided percutaneous platelet rich plasma injection
Sponsors: University of Michigan; University of Michigan
Recruiting - verified May 2012 - Conditions: Hand Eczema; Foot Eczema
Interventions: Drug: Retapamulin 1% ointment; Drug: Placebo
Sponsors: Mount Sinai School of Medicine; Gary Goldenberg
Recruiting - verified May 2012 - Condition: Acute Low Back Pain
Interventions: Drug: Naproxen; Drug: Cyclobenzaprine; Drug: Oxycodone/ acetaminophen
Sponsors: Montefiore Medical Center; Montefiore Medical Center
Recruiting - verified April 2012 - Conditions: Ulcerative Colitis; Left-sided Ulcerative Colitis; Distal Ulcerative Colitis
Interventions: Drug: Zoenasa-1:4; Drug: Mesalamine Enema
Sponsors: Altheus Therapeutics, Inc.; Altheus Therapeutics, Inc.
Not yet recruiting - verified April 2012 - Conditions: Anterior Cruciate Ligament Reconstruction; Regional Anesthesia, Saphenous Nerve Block
Interventions: Drug: Bupivacaine Only; Drug: Bupivacaine with 2 ml of Dexamethasone; Drug: Bupivacaine with 4 mg of Dexamethasone
Sponsors: Hospital for Special Surgery, New York; Hospital for Special Surgery, New York
Not yet recruiting - verified April 2012 - Conditions: Emphysema; Poor Sleep Quality
Interventions: Drug: Budesonide/formoterol 160/4.5 mcg; Drug: Placebo
Sponsors: Temple University; Temple University
Recruiting - verified May 2012 - Condition: Retinal Vein Occlusion
Intervention: Drug: Dexamethasone with rescue ranibizumab
Sponsors: Wills Eye; Wills Eye
Not yet recruiting - verified April 2012 - Condition: Brain Tumor
Intervention: Drug: Sulfasalazine
Sponsors: University of Alabama at Birmingham; University of Alabama at Birmingham
Recruiting - verified April 2012 - Conditions: Schizophrenia; Schizoaffective Disorder
Intervention: Drug: salsalate
Sponsors: Massachusetts General Hospital; Massachusetts General Hospital; National Institutes of Health (NIH)
Recruiting - verified April 2012 - Conditions: Congenital Heart Disease; Disorder of Fetus or Newborn
Interventions: Drug: Methylprednisolone; Drug: Placebo
Sponsors: Medical University of South Carolina; Medical University of South Carolina; National Heart, Lung, and Blood Institute (NHLBI); National Institutes of Health (NIH)
Not yet recruiting - verified April 2012 - Condition: Prostate Cancer
Interventions: Drug: abiraterone acetate; Drug: prednisone; Drug: veliparib
Sponsors: National Cancer Institute (NCI); University of Chicago; National Cancer Institute (NCI)
Recruiting - verified April 2012 - Condition: Asthma
Interventions: Drug: Fluticasone propionate DPI Dose 1; Drug: Fluticasone propionate DPI Dose 2; Drug: Fluticasone propionate DPI Dose 3; Drug: Fluticasone propionate DPI Dose 4; Other: Placebo DPI; Drug: Flovent Diskus 250 mcg
Sponsors: Teva Pharmaceutical Industries; Teva Pharmaceutical Industries
Not yet recruiting - verified May 2012 - Condition: COPD
Interventions: Drug: roflumilast; Drug: placebo
Sponsors: University of Alabama at Birmingham; University of Alabama at Birmingham
Not yet recruiting - verified April 2012 - Conditions: Ischemic Stroke; Transient Ischemic Attack (TIA)
Intervention: Other: Vitamin E tocotrienol (TCT) pills ; Low dose Aspirin
Sponsors: Ohio State University; Chandan K Sen; Government of Malaysia
Recruiting - verified April 2012 - Condition: Multiple Myeloma
Interventions: Drug: Carfilzomib; Drug: Lenalidomide; Drug: Dexamethasone
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified March 2012 - Condition: Asthma
Interventions: Drug: FF/GSK573719; Drug: FF/GSK573719; Drug: FF/GSK573719; Drug: FF/GSK573719; Drug: FF/GSK573719; Drug: FF; Drug: FF/VI
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified May 2012 - Condition: Herpes Labialis
Intervention: Drug: acyclovir/hydrocortisone cream
Sponsors: Meda Pharmaceuticals; Meda Pharmaceuticals; TKL Research, Inc.
Recruiting - verified April 2012 - Conditions: Diabetic Macular Edema.; Non-proliferative Diabetic Retinopathy; Proliferative Diabetic Retinopathy
Interventions: Drug: dexamethasone intravitreal implant; Drug: intravitreal bevacizumab
Sponsors: Retina Macula Institute; Retina Macula Institute; Allergan
Recruiting - verified April 2012 - Condition: Healthy Volunteers
Interventions: Drug: Standard dose BG00012; Drug: Aspirin placebo; Drug: Aspirin; Drug: Escalating doses of BG00012; Drug: BG00012 placebo
Sponsors: Biogen Idec; Biogen Idec
Recruiting - verified April 2012 - Condition: CD20-positive B-cell Non-Hodgkin Lymphoma
Interventions: Drug: Part 1, Cohort 1; Drug: Part 1, Cohort 2; Drug: Part 1, Cohort 3; Drug: Part 2, Cohort 1; Drug: Part 2, Cohort 2
Sponsors: Janssen Research & Development, LLC; Janssen Research & Development, LLC; Pharmacyclics
Not yet recruiting - verified May 2012 - Condition: Advanced Solid Tumors, Excluding Breast Cancer
Interventions: Drug: caffeine; Drug: diclofenac; Drug: omeprazole; Drug: midazolam; Drug: TKI258
Sponsors: Novartis; Novartis Pharmaceuticals
Not yet recruiting - verified May 2012 - Condition: Pain
Interventions: Drug: Ibuprofen/acetaminophen; Drug: Ibuprofen/acetaminophen; Drug: Ibuprofen/acetaminophen; Drug: Ibuprofen; Drug: Placebo
Sponsors: Pfizer; Pfizer
Not yet recruiting - verified April 2012 - Condition: Heart Disease Congenital Complex
Interventions: Drug: Hydrocortisone; Drug: Normal Saline
Sponsors: University of Alabama at Birmingham; University of Alabama at Birmingham
Recruiting - verified May 2012 - Conditions: Orthostatic Hypotension; Hemodynamic Instability; Fever; Hypothermia
Interventions: Drug: Hydrocortisone; Drug: Hydrocortisone
Sponsors: Cedars-Sinai Medical Center; Cedars-Sinai Medical Center
Recruiting - verified March 2012 - Condition: Oral Chronic Graft vs Host Disease
Interventions: Drug: Clobetasol Oral Rinse; Procedure: Chronic GVHD organ staging; Procedure: Assessment of Oral GVHD; Behavioral: Numeric rating scales for oral pain; Behavioral: Oral Global Scale; Behavioral: Painometer (POM) Assessment; Behavioral: Oral Health Impact Profile-OHIP-14; Procedure: Biopsy of buccal mucosa; Procedure: Short ACTH stimulation test
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified January 2012 - Condition: Asthma
Interventions: Drug: Fluticasone Furoate; Drug: Fluticasone Propionate; Drug: Placebo
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Not yet recruiting - verified March 2012 - Condition: Headache
Interventions: Drug: BAY1019036; Drug: Acetaminophen; Drug: Placebo
Sponsors: Bayer; Bayer
Recruiting - verified May 2012 - Conditions: Prostatic Neoplams; Prostate Cancer; Neoplasm, Prostate; Neoplasm,Prostatic
Interventions: Drug: AMG 386; Drug: Abiraterone; Drug: Prednisone
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified February 2012 - Conditions: Blood Donor; Leukocyte Transfusion; Granulocyte Colony-Stimulation Factor; Blood Component Removal
Interventions: Drug: Filgrastim (G-CSF); Drug: Dexamethasone
Sponsors: National Institutes of Health Clinical Center (CC); National Institutes of Health Clinical Center (CC)
Recruiting - verified February 2012 - Condition: Rheumatoid Arthritis
Interventions: Drug: Triple Therapy; Drug: TNF inhibitors
Sponsors: Columbia University; Columbia University; National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Recruiting - verified March 2012 - Condition: Asthma
Interventions: Drug: Fluticasone propionate 100mcg; Drug: Placebo; Drug: Vilanterol
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Not yet recruiting - verified April 2012 - Condition: Cardiovascular Disease
Interventions: Drug: Efavirenz; Drug: Rilpivirine
Sponsors: Indiana University; Indiana University; Janssen Services, LLC
Not yet recruiting - verified April 2012 - Condition: Preeclampsia
Interventions: Drug: Aspirin; Drug: placebo
Sponsors: Washington University School of Medicine; Washington University School of Medicine
Recruiting - verified March 2012 - Condition: Other Acute Postoperative Pain
Interventions: Drug: Indomethacin; Drug: Indomethacin; Drug: Indomethacin; Drug: Celecoxib; Drug: Placebo
Sponsors: Iroko Pharmaceuticals, LLC; Iroko Pharmaceuticals, LLC
Recruiting - verified February 2012 - Condition: Multiple Myeloma
Interventions: Drug: DPACE (Dexamethasone, Cisplatin, Adriamycin, Cyclophosphamide, Etoposide); Procedure: Transplant 1 (Velcade, Thalidomide, Dexamethasone, Melphalan); Procedure: Transplant 2 (Velcade, Gemcitabine, Carmustine, Dexamethasone, Melphalan); Drug: Consolidation VDT-PACE (Velcade, Dexamethasone, Thalidomide, Cisplatin, Adriamycin, Cyclophosphamide, Etoposide); Drug: Maintenance Year 1 (Velcade, Thalidomide, Dexamethasone OR Velcade, Revlimid, Dexamethasone OR Velcade, Cyclophosphamide, Dexamethasone in 28 day cycles x 12); Drug: Maintenance Year 2 (Revlimid and Dexamethasone in 28 day cycles x 12)
Sponsors: University of Iowa; University of Iowa; National Cancer Institute (NCI)
Not yet recruiting - verified March 2012 - Conditions: Asthma; Chronic Obstructive Pulmonary Disease; Obstructive Sleep Apnea
Intervention: Drug: Inhaled Fluticasone Propionate
Sponsors: Department of Veterans Affairs; Department of Veterans Affairs
Not yet recruiting - verified March 2012 - Condition: Shoulder Pain
Interventions: Drug: Synera® (lidocaine 70 mg and tetracaine 70 mg) topical patch; Drug: Triamcinolone Acetonide
Sponsors: Injury Care Medical Center; Injury Care Medical Center; Nuvo Research Inc.
Recruiting - verified March 2012 - Conditions: Shoulder Pain; Injury of Shoulder Region; Disorder of Shoulder; Disorder of Rotator Cuff; Disorder of Tendon of Biceps
Interventions: Drug: Dexamethasone; Drug: Bupivacaine
Sponsors: Lifespan; Lifespan; Tufts Medical Center; United States Naval Medical Center, Portsmouth
Not yet recruiting - verified March 2012 - Condition: AL Amyloidosis
Interventions: Drug: Pomalidomide; Drug: Dexamthasone
Sponsors: Boston Medical Center; Boston Medical Center; Celgene Corporation
Not yet recruiting - verified February 2012 - Condition: Postoperative Complications
Interventions: Drug: Placebo-saline; Drug: Dexamethasone 4 mg; Drug: Dexamethasone 8 mg
Sponsors: NorthShore University HealthSystem Research Institute; NorthShore University HealthSystem Research Institute
Recruiting - verified March 2012 - Condition: Healthy Controls
Interventions: Radiation: Integrated MR-PET scan; Drug: Ketorolac; Drug: Morphine
Sponsors: Massachusetts General Hospital; Massachusetts General Hospital
Recruiting - verified April 2012 - Condition: Cardiovascular Disease
Interventions: Dietary Supplement: ResA; Dietary Supplement: Resveratrol; Dietary Supplement: Placebo
Sponsors: University of California, Davis; University of California, Davis; Gateway Health Alliance
Not yet recruiting - verified March 2012 - Condition: Osteoarthritis, Knee
Interventions: Drug: Naproxen; Drug: Placebo
Sponsors: Analgesic Solutions; Analgesic Solutions
Recruiting - verified February 2012 - Condition: Multiple Myeloma
Interventions: Drug: Pomalidomide; Drug: Pegylated Liposomal Doxorubicin (PLD); Drug: Dexamethasone
Sponsors: Oncotherapeutics; Oncotherapeutics; Celgene Corporation
Recruiting - verified February 2012 - Conditions: Asthma; Allergic Rhinitis
Interventions: Drug: Alvesco/Omnaris, QVAR/Beconase, Placebo/Placebo; Drug: Alvesco/Omnaris, Placebo/Placebo, QVAR/Beconase; Drug: QVAR/Beconase, Alvesco/Omnaris, Placebo/Placebo; Drug: QVAR/Beconase, Placebo/Placebo, Alvesco/Omnaris; Drug: Placebo/Placebo, Alvesco/Omnaris, QVAR/Beconase; Drug: Placebo/Placebo, QVAR/Beconase, Alvesco/Omnaris
Sponsors: West Penn Allegheny Health System; West Penn Allegheny Health System
Not yet recruiting - verified March 2012 - Condition: Ulcerative Colitis
Interventions: Drug: Mesalamine; Drug: Prednisone; Drug: Corticosteroids followed by mesalamine (Pentasa)
Sponsors: Connecticut Children's Medical Center; Connecticut Children's Medical Center; National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Not yet recruiting - verified April 2012 - Condition: Multiple Myeloma
Interventions: Drug: carfilzomib; Drug: Dexamethasone; Drug: Clarithromycin; Drug: Lenalidomide; Drug: Dexamethasone; Drug: Lenalidomide
Sponsors: Weill Medical College of Cornell University; Weill Medical College of Cornell University; Onyx Therapeutics, Inc.
Not yet recruiting - verified March 2012 - Conditions: Heroin Dependence; Opioid-Related Disorders
Intervention:
Sponsors: Wayne State University; Wayne State University; National Institute on Drug Abuse (NIDA)
Recruiting - verified February 2012 - Conditions: Contiguous Stage II Adult Diffuse Large Cell Lymphoma; Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma; Stage I Adult Diffuse Large Cell Lymphoma; Stage III Adult Diffuse Large Cell Lymphoma; Stage IV Adult Diffuse Large Cell Lymphoma
Interventions: Biological: rituximab; Drug: cyclophosphamide; Drug: doxorubicin hydrochloride; Drug: vincristine sulfate; Drug: prednisone; Other: laboratory biomarker analysis; Other: pharmacological study
Sponsors: Fox Chase Cancer Center; Fox Chase Cancer Center; Genentech
Not yet recruiting - verified March 2012 - Conditions: Psoriasis; Cardiovascular Disease
Interventions: Drug: Adalimumab (Humira); Drug: Placebo Injection; Other: NB-UVB phototherapy
Sponsors: University of Pennsylvania; University of Pennsylvania
Not yet recruiting - verified March 2012 - Condition: Fever
Interventions: Drug: Intravenous Ibuprofen; Drug: Acetaminophen (Standard of Care)
Sponsors: Columbia University; Columbia University; Cumberland Pharmaceuticals
Recruiting - verified February 2012 - Condition: Myeloma
Interventions: Drug: Lenalidomide; Drug: Bortezomib; Drug: Siltuximab; Drug: Dexamethasone; Behavioral: Questionnaires
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Janssen Services, LLC
Recruiting - verified May 2012 - Condition: Epicondylitis of the Elbow
Interventions: Drug: Naproxen; Drug: Synera patch twice daily; Drug: Synera patch for 12hrs/day; Drug: Naproxen; Drug: Synera; Drug: Synera
Sponsors: International Clinical Research Institute; International Clinical Research Institute
Not yet recruiting - verified January 2012 - Condition: Post Traumatic Stress Disorder
Interventions: Other: Hydrocortisone augmented Prolonged Exposure Therapy; Other: Prolonged exposure therapy with placebo administration
Sponsors: Bronx VA Medical Center; Bronx VA Medical Center; Department of Defense
Recruiting - verified October 2011 - Condition: Acute Lymphoblastic Leukemia
Interventions: Drug: Everolimus; Drug: Prednisone; Drug: Vincristine; Drug: PEG-Asparaginase; Drug: Doxorubicin; Drug: Dexrazoxane
Sponsors: Dana-Farber Cancer Institute; Dana-Farber Cancer Institute; Novartis
Recruiting - verified January 2012 - Condition: Acne Vulgaris
Interventions: Drug: Epiduo Gel; Drug: Retin-A Micro Microsphere 0.1%
Sponsors: Galderma Laboratories, L.P.; Galderma Laboratories, L.P.
Recruiting - verified March 2012 - Conditions: Cholangiocarcinoma; Liver Neoplasms
Interventions: Drug: floxuridine, dexamethasone; Drug: floxuridine, dexamethasone, gemcitabine hydrochloride; Drug: floxuridine, dexamethasone, gemcitabine hydrochloride, oxaliplatin
Sponsors: Washington University School of Medicine; Washington University School of Medicine
Recruiting - verified May 2012 - Condition: Asthma
Interventions: Drug: Fluticasone, Budesonide, Beclomethasone; Drug: Fluticasone, Beclomethasone, Budesonide; Drug: Budesonide, Fluticasone, Beclomethasone; Drug: Budesonide, Beclomethasone, Fluticasone; Drug: Beclomethasone, Fluticasone, Budesonide; Drug: Beclomethasone, Budesonide, Fluticasone
Sponsors: West Penn Allegheny Health System; West Penn Allegheny Health System
Recruiting - verified February 2012 - Condition: Schizophrenia
Interventions: Drug: Anti-inflammatory Combination Therapy; Drug: Placebo
Sponsors: University of Maryland; University of Maryland
Not yet recruiting - verified January 2012 - Condition: Kidney Transplant
Interventions: Drug: Tacrolimus Withdrawal +MMF +Prednisone; Drug: MMF/Tacrolimus/Prednisone
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified January 2012 - Condition: Psoriasis
Intervention: Drug: etanercept
Sponsors: Amgen; Amgen
Recruiting - verified April 2012 - Conditions: Stage I Multiple Myeloma; Stage II Multiple Myeloma; Stage III Multiple Myeloma
Interventions: Drug: dalteparin; Drug: lenalidomide; Drug: dexamethasone; Other: laboratory biomarker analysis
Sponsors: USC/Norris Comprehensive Cancer Center; USC/Norris Comprehensive Cancer Center; National Cancer Institute (NCI); Celgene Corporation
Recruiting - verified January 2012 - Condition: Diabetes Mellitus, Type 2
Interventions: Drug: PL2200 Aspirin Capsules; Drug: Immediate-Release Aspirin Tablets; Drug: Enteric-coated aspirin caplets
Sponsors: PLx Pharma; PLx Pharma
Recruiting - verified January 2012 - Conditions: Osteoarthritis of the Knee; Coagulopathy
Intervention: Drug: PENNSAID (diclofenac sodium solution topical)
Sponsors: Arthritis Treatment Center, Maryland; Nathan Wei, MD, FACP, FACR:; Covidien; Arthritis Treatment Center, Maryland
Recruiting - verified February 2012 - Conditions: Prostate Cancer; Castration Resistant Prostate Cancer; Pain; Prostatic Neoplasms
Interventions: Drug: cabozantinib; Drug: mitoxantrone; Drug: prednisone
Sponsors: Exelixis; Exelixis
Recruiting - verified April 2012 - Conditions: Neuralgia; Postherpetic Neuralgia; Reflex Sympathetic Dystrophy
Interventions: Drug: Pennsaid topical 1.5% diclofenac; Drug: Placebo (2.3% DMSO solution)
Sponsors: Massachusetts General Hospital; Massachusetts General Hospital
Recruiting - verified March 2012 - Condition: Asthma
Interventions: Drug: RNS60; Drug: Normal Saline; Drug: Budesonide
Sponsors: Revalesio Corporation; Revalesio Corporation
Not yet recruiting - verified January 2012 - Conditions: Pain; Total Knee Arthroplasty
Interventions: Drug: Dexamethasone; Drug: Ropivacaine
Sponsors: University of New Mexico; University of New Mexico
Not yet recruiting - verified April 2012 - Conditions: Anemia; Unexplained Anemia
Interventions: Drug: Salsalate; Drug: Salsalate placebo
Sponsors: Duke University; Duke University; National Institute on Aging (NIA)
Not yet recruiting - verified January 2012 - Condition: Multiple Myeloma
Interventions: Drug: ACE-011; Drug: Lenalidomide; Drug: Dexamethasone
Sponsors: Massachusetts General Hospital; Massachusetts General Hospital
Recruiting - verified May 2012 - Conditions: Prostatic Neoplasm; Prostate Cancer; Prostatic Adenocarcinoma; Hormone Refractory Prostate Cancer; Stage IV Prostate Carcinoma
Interventions: Drug: Abiraterone acetate plus prednisone; Drug: Abiraterone acetate plus prednisone; Drug: Abiraterone acetate plus prednisone
Sponsors: University of Washington; University of Washington; Janssen, LP
Not yet recruiting - verified January 2012 - Condition: Acute Respiratory Distress Syndrome
Interventions: Drug: Aspirin; Drug: Lactose powder
Sponsors: Mayo Clinic; Ognjen Gajic; Beth Israel Deaconess Medical Center; Montefiore Medical Center; Vanderbilt University
Not yet recruiting - verified January 2012 - Condition: Anterior Uveitis
Interventions: Drug: 40 mg/mL Dexamethasone phosphate ophthalmic solution; Drug: Prednisolone Acetate (1%) Eyedrops; Drug: 100 mM sodium citrate buffer solution; Drug: Placebo Eyedrops
Sponsors: Eyegate Pharmaceuticals, Inc.; Eyegate Pharmaceuticals, Inc.
Recruiting - verified May 2012 - Condition: Psoriasis
Intervention:
Sponsors: Massachusetts General Hospital; Massachusetts General Hospital; Immunex Corporation
Recruiting - verified February 2012 - Condition: Acne Vulgaris
Interventions: Drug: Adapalene + benzoyl peroxide samples; Drug: Adapalene + benzoyl peroxide from standard tube
Sponsors: Wake Forest University; Wake Forest University; Galderma Laboratories, L.P.
Recruiting - verified January 2012 - Condition: Prostate Cancer
Interventions: Drug: Cabazitaxel; Drug: Prednisone; Drug: Carboplatin
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Sanofi-Aventis
Not yet recruiting - verified January 2012 - Condition: Asthma
Interventions: Drug: Mometasone Furoate (MF) Metered Dose Inhaler (MDI), 25 mcg; Drug: Mometasone Furoate (MF) Metered Dose Inhaler (MDI), 50 mcg; Drug: Mometasone Furoate (MF) Metered Dose Inhaler (MDI), 100 mcg; Drug: Mometasone Furoate (MF) Dry Powder Inhaler (DPI), 100 mcg; Drug: Placebo Metered Dose Inhaler (MDI); Drug: Placebo Dry Powder Inhaler (DPI)
Sponsors: Schering-Plough; Schering-Plough
Recruiting - verified April 2012 - Conditions: Adenocarcinoma of the Prostate; Hormone-resistant Prostate Cancer; Recurrent Prostate Cancer; Stage IV Prostate Cancer
Interventions: Drug: abiraterone acetate; Drug: prednisone; Other: laboratory biomarker analysis; Other: pharmacological study
Sponsors: Fred Hutchinson Cancer Research Center; Fred Hutchinson Cancer Research Center; National Cancer Institute (NCI)
Not yet recruiting - verified December 2011 - Condition: Multiple Myeloma
Intervention: Drug: Vorinostat, Lenalinomide and Dexamethasone
Sponsors: Hackensack University Medical Center; Hackensack University Medical Center; Merck Sharp & Dohme Corp., Inc.
Recruiting - verified December 2011 - Condition: Alzheimer's Disease
Interventions: Drug: Resveratrol; Drug: Placebo
Sponsors: Alzheimer's Disease Cooperative Study (ADCS); Alzheimer's Disease Cooperative Study (ADCS); National Institute on Aging (NIA)
Recruiting - verified May 2012 - Condition: Chemotherapy-induced Nausea and Vomiting
Interventions: Drug: Rolapitant; Drug: Granisetron; Drug: Dexamethasone
Sponsors: Tesaro, Inc.; Tesaro, Inc.; Covance; Pharm Olam Pharmaceuticals Ltd.; Parexel; Biomedical Systems Corporation; XenoBiotic Laboratories
Recruiting - verified May 2012 - Condition: Chemotherapy-induced Nausea and Vomiting
Interventions: Drug: Rolapitant; Drug: Granisetron; Drug: Dexamethasone
Sponsors: Tesaro, Inc.; Tesaro, Inc.; Covance; Pharm Olam Pharmaceuticals Ltd.; Parexel; Biomedical Systems Corporation
Recruiting - verified May 2012 - Condition: Rheumatoid Arthritis
Interventions: Biological: Certolizumab pegol + Methotrexate (CZP + MTX); Biological: Adalimumab + Methotrexate (ADA + MTX)
Sponsors: UCB, Inc.; UCB, Inc.
Recruiting - verified May 2012 - Condition: Multiple Myeloma
Interventions: Drug: Pomalidomide; Drug: Bortezomib; Drug: Dexamethasone
Sponsors: Celgene Corporation; Celgene Corporation; Multiple Myeloma Research Consortium
Recruiting - verified April 2012 - Conditions: Chronic Lymphocytic Leukemia (CLL); Small Lymphocytic Lymphoma (SLL)
Interventions: Drug: High Dose Methylprednisolone; Drug: Ofatumumab; Drug: Lenalidomide; Drug: Sargramostim
Sponsors: H. Lee Moffitt Cancer Center and Research Institute; H. Lee Moffitt Cancer Center and Research Institute; GlaxoSmithKline; Celgene Corporation
Recruiting - verified January 2012 - Condition: Chemotherapy-induced Nausea and Vomiting
Interventions: Drug: Rolapitant; Drug: Granisetron; Drug: dexamethasone
Sponsors: Tesaro, Inc.; Tesaro, Inc.; Pharm Olam Pharmaceuticals Ltd.; Parexel; Covance; Biomedical Systems Corporation; XenoBiotic Laboratories
Recruiting - verified May 2012 - Condition: Angiotensin-converting Enzyme (ACE) Inhibitor-associated Angioedema
Interventions: Drug: HOE-140; Other: Placebo
Sponsors: Vanderbilt University; Vanderbilt University; University of California, San Diego; Massachusetts General Hospital; University of California, Los Angeles
Recruiting - verified April 2012 - Conditions: Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma
Interventions: Drug: High Dose Methylprednisolone; Drug: Ofatumumab; Drug: Lenalidomide; Drug: Sargramostim
Sponsors: H. Lee Moffitt Cancer Center and Research Institute; H. Lee Moffitt Cancer Center and Research Institute; GlaxoSmithKline; Celgene Corporation
Recruiting - verified January 2012 - Condition: Postoperative Dental Pain
Interventions: Drug: PF-05089771; Other: Placebo; Drug: PF-05089771; Other: Placebo; Drug: PF-05089771; Other: Placebo; Drug: Ibuprofen; Other: Placebo; Other: Placebo; Other: Placebo
Sponsors: Pfizer; Pfizer
Recruiting - verified April 2012 - Condition: Postsurgical Dental Implant Surgery Pain
Intervention: Drug: Ketorolac Tromethamine Nasal Spray
Sponsors: Hersh, Elliot V., DMD, MS, PhD; Hersh, Elliot V., DMD, MS, PhD
Recruiting - verified December 2011 - Condition: Ulcerative Colitis
Interventions: Drug: Budesonide; Drug: Placebo; Procedure: Procedure/Surgery: Blood sampling, endoscopy
Sponsors: Santarus; Santarus
Recruiting - verified May 2012 - Condition: Macular Edema
Interventions: Drug: dexamethasone Intravitreal Implant; Drug: ranibizumab
Sponsors: Allergan; Allergan
Recruiting - verified May 2012 - Conditions: Contiguous Stage II Mantle Cell Lymphoma; Noncontiguous Stage II Mantle Cell Lymphoma; Stage I Mantle Cell Lymphoma; Stage III Mantle Cell Lymphoma; Stage IV Mantle Cell Lymphoma
Interventions: Biological: ofatumumab; Drug: cyclophosphamide; Drug: dexamethasone; Drug: doxorubicin hydrochloride; Drug: vincristine sulfate; Drug: cytarabine; Procedure: autologous hematopoietic stem cell transplantation; Drug: methotrexate
Sponsors: Roswell Park Cancer Institute; Roswell Park Cancer Institute; National Comprehensive Cancer Network
Recruiting - verified April 2012 - Condition: Duration of Interscalene Block
Interventions: Other: ropivacaine plus dexamethasone anesthetic; Other: ropivacaine plus saline plus dexamethasone anesthetic
Sponsors: The Cleveland Clinic; The Cleveland Clinic
Recruiting - verified December 2011 - Condition: Polycystic Ovary Syndrome
Interventions: Drug: Salsalate; Drug: Salsalate
Sponsors: Indiana University; Indiana University
Recruiting - verified February 2012 - Conditions: Sarcoma; Chemotherapy-induced Nausea and Vomiting; Effects of Chemotherapy; Adverse Effects of Medical Drugs
Interventions: Drug: Fosaprepitant; Drug: Dexamethasone; Drug: 5HT3 receptor antagonist; Drug: Ifosfamide-based chemotherapy (AI); Drug: Doxorubicin; Drug: Mesna; Drug: Ifosfamide; Drug: Vincristine
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Merck
Not yet recruiting - verified March 2012 - Conditions: Prostate Cancer Metastatic; Hormone Refractory Prostate Cancer
Interventions: Biological: sipuleucel-T; Drug: abiraterone acetate
Sponsors: Dendreon; Dendreon
Recruiting - verified May 2012 - Conditions: Pre-diabetes; Impaired Fasting Glucose; Impaired Glucose Tolerance
Intervention: Drug: Dexamethasone
Sponsors: University of Vermont; University of Vermont; Merck
Not yet recruiting - verified December 2011 - Condition: Prostate Cancer
Interventions: Drug: GDC-0068; Drug: GDC-0980; Drug: placebo; Drug: abiraterone; Drug: prednisone
Sponsors: Genentech; Genentech
Recruiting - verified April 2012 - Condition: Multiple Myeloma
Interventions: Drug: Ganetespib Dexamethasone; Drug: Bortezomib; Drug: Dexamethasone
Sponsors: Emory University; Emory University; Multiple Myeloma Research Consortium
Recruiting - verified March 2012 - Conditions: Graft Versus Host Disease; Steroid Refractory GVHD; Acute GVH Disease
Intervention: Drug: Infliximab and Basiliximab as combination therapy
Sponsors: Nationwide Children's Hospital; Nationwide Children's Hospital; Ohio State University Comprehensive Cancer Center
Not yet recruiting - verified December 2011 - Condition: Pulmonary Sarcoidosis
Interventions: Dietary Supplement: N-acetyl-cysteine; Drug: Placebo
Sponsors: National Jewish Health; National Jewish Health; American Thoracic Society
Recruiting - verified April 2012 - Conditions: Acute Lymphoblastic Leukemia; Precursor B-Cell Lymphoblastic Leukemia; Precursor T-Cell Lymphoblastic Leukemia
Interventions: Drug: Decitabine; Drug: Vorinostat; Drug: Vincristine; Drug: Dexamethasone; Drug: Mitoxantrone; Drug: Pegaspargase; Drug: Methotrexate
Sponsors: Therapeutic Advances in Childhood Leukemia Consortium; Therapeutic Advances in Childhood Leukemia Consortium
Recruiting - verified March 2012 - Condition: Psoriasis
Interventions: Drug: CNTO 1959 (5 mg); Drug: CNTO 1959 (15 mg); Drug: CNTO 1959 (50 mg); Drug: CNTO 1959 (100 mg); Drug: CNTO 1959 (200 mg); Drug: Adalimumab; Drug: Placebo to CNTO 1959 (100 mg)
Sponsors: Janssen Inc.; Janssen Inc.
Recruiting - verified February 2012 - Condition: Multiple Myeloma
Interventions: Drug: Bendamustine; Drug: Bortezomib; Drug: Lenalidomide; Drug: Dexamethasone
Sponsors: Loyola University; Loyola University
Recruiting - verified December 2011 - Conditions: Peripheral Neuropathy; Type 1 Diabetes
Intervention: Drug: Salsalate
Sponsors: University of Michigan; University of Michigan
Recruiting - verified December 2011 - Condition: Allergic Conjunctivitis
Interventions: Drug: AL-4943A Ophthalmic Solution; Drug: AL-4943A Ophthalmic Solution Vehicle; Drug: Pataday
Sponsors: Alcon Research; Alcon Research
Recruiting - verified January 2012 - Conditions: Familial Adenomatous Polyposis; Attenuated Familial Adenomatous Polyposis
Interventions: Drug: Eflornithine plus Sulindac; Drug: Eflornithine and Placebo; Drug: Sulindac and Placebo
Sponsors: Cancer Prevention Pharmaceuticals, Inc.; Cancer Prevention Pharmaceuticals, Inc.
Not yet recruiting - verified March 2012 - Condition: Asthma
Interventions: Drug: Placebo; Drug: Flovent Diskus; Drug: Fluticasone propionate DPI Dose 1; Drug: Fluticasone propionate DPI Dose 2; Drug: Fluticasone propionate DPI Dose 3; Drug: Fluticasone propionate DPI Dose 4
Sponsors: Teva Pharmaceutical Industries; Teva Pharmaceutical Industries; PPD
Recruiting - verified May 2012 - Condition: Senile Purpura
Intervention: Drug: adapalene gel 0.3%
Sponsors: Multispecialty Aesthetic Clinical Research Organization; Multispecialty Aesthetic Clinical Research Organization; Galderma Laboratories, L.P.
Recruiting - verified April 2012 - Condition: Asthma
Interventions: Drug: ADVAIR 100/50mcg; Drug: ADVAIR 250/50mcg; Drug: ADVAIR 500/50mcg; Drug: FLOVENT 100mcg; Drug: FLOVENT 250mcg; Drug: FLOVENT 500mcg
Sponsors: GlaxoSmithKline; GlaxoSmithKline; Parexel
Recruiting - verified May 2012 - Condition: Cataract
Interventions: Drug: Loteprednol etabonate; Drug: Prednisolones acetate
Sponsors: Bausch & Lomb, Inc.; Bausch & Lomb, Inc.
Not yet recruiting - verified November 2011 - Condition: PTSD
Interventions: Drug: Dexamethasone; Drug: Dexamethasone
Sponsors: Emory University; Emory University; National Institute of Mental Health (NIMH)
Recruiting - verified November 2011 - Condition: Acne Vulgaris
Intervention: Drug: RA-18C3
Sponsors: XBiotech, Inc.; XBiotech, Inc.
Recruiting - verified April 2012 - Condition: Neuroendocrine Tumor
Intervention: Dietary Supplement: Resveratrol
Sponsors: University of Wisconsin, Madison; University of Wisconsin, Madison
Recruiting - verified February 2012 - Condition: Migraine
Interventions: Drug: Ketorolac; Drug: Placebo
Sponsors: Akron Children's Hospital; Akron Children's Hospital
Recruiting - verified February 2012 - Condition: Asthma
Interventions: Drug: Mometasone Furoate/Formoterol MDI 100/5 mcg; Drug: Mometasone Furoate/Formoterol MDI 200/5 mcg; Drug: Mometasone Furoate MDI 100 mcg; Drug: Mometasone Furoate MDI 200 mcg; Drug: Albuterol 90 mcg /salbutamol 100 mcg HFA MDI; Drug: Prednisone/prednisolone
Sponsors: Schering-Plough; Schering-Plough
Recruiting - verified April 2012 - Condition: Myopia
Intervention: Drug: Bromfenac
Sponsors: Virdi Eye Clinic; Virdi Eye Clinic
Recruiting - verified November 2011 - Condition: Peripheral Arterial Disease
Intervention: Procedure: Administration of dexamethasone to SFA/popliteal adventitia
Sponsors: University of California, San Francisco; University of California, San Francisco
Recruiting - verified January 2012 - Condition: Atopic Dermatitis
Intervention: Drug: Fluocinonide cream
Sponsors: Wake Forest University; Wake Forest University; Medicis Pharmaceutical Corporation
Recruiting - verified November 2011 - Condition: Hidradenitis Suppurativa (HS)
Interventions: Biological: adalimumab; Biological: placebo; Biological: adalimumab
Sponsors: Abbott; Abbott
Recruiting - verified March 2012 - Condition: Hidradenitis Suppurativa (HS)
Interventions: Biological: adalimumab; Biological: placebo; Biological: adalimumab
Sponsors: Abbott; Abbott
Recruiting - verified December 2011 - Conditions: Macular Edema; Cystoid Macular Edema; Uveal Melanoma; Radiation Maculopathy; Radiation Retinopathy
Intervention: Drug: Ozurdex (Dexamethasone intravitreal implant )
Sponsors: Wills Eye; Arman Mashayekhi; Allergan
Not yet recruiting - verified November 2011 - Condition: Multiple Myeloma
Interventions: Biological: Elotuzumab; Drug: Bortezomib; Drug: Dexamethasone; Drug: Dexamethasone; Drug: Dexamethasone; Drug: Dexamethasone
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb; Abbott Biotherapeutics Corp.
Recruiting - verified February 2012 - Conditions: Diarrhea; Hormone-resistant Prostate Cancer; Recurrent Prostate Cancer; Stage I Prostate Cancer; Stage IIA Prostate Cancer; Stage IIB Prostate Cancer; Stage III Prostate Cancer; Stage IV Prostate Cancer
Interventions: Drug: cabazitaxel; Drug: prednisone; Drug: octreotide pamoate; Other: questionnaire administration; Drug: octreotide acetate
Sponsors: USC/Norris Comprehensive Cancer Center; USC/Norris Comprehensive Cancer Center; National Cancer Institute (NCI); Sanofi-Aventis
Not yet recruiting - verified May 2012 - Condition: Complicated Skin and Soft Tissue Infection
Interventions: Drug: Ceftaroline fosamil; Drug: Vancomycin; Drug: Aztreonam
Sponsors: AstraZeneca; AstraZeneca; Cerexa, Inc.
Not yet recruiting - verified March 2012 - Condition: Asthma
Interventions: Drug: ADVAIR 100/50mcg; Drug: ADVAIR 250/50mcg; Drug: FLOVENT 100mcg; Drug: FLOVENT 250mcg
Sponsors: GlaxoSmithKline; GlaxoSmithKline; Parexel
Recruiting - verified May 2012 - Condition: Asthma
Intervention: Drug: Budesonide
Sponsors: University of California, San Francisco; University of California, San Francisco; National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified November 2011 - Condition: Painful Diabetic Peripheral Neuropathy
Interventions: Drug: pregabalin; Drug: placebo
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2012 - Condition: Multiple Myeloma
Interventions: Drug: masitinib 6 mg/kg/day; Drug: placebo
Sponsors: AB Science; AB Science
Recruiting - verified November 2011 - Conditions: Adenocarcinoma of the Prostate; Hormone-resistant Prostate Cancer; Recurrent Prostate Cancer; Stage IV Prostate Cancer
Interventions: Drug: docetaxel; Drug: pasireotide; Drug: prednisone
Sponsors: Barbara Ann Karmanos Cancer Institute; Barbara Ann Karmanos Cancer Institute; National Cancer Institute (NCI)
Recruiting - verified November 2011 - Condition: Colitis, Ulcerative
Intervention: Drug: SRT2104
Sponsors: GlaxoSmithKline; Sirtris, a GSK Company; GlaxoSmithKline
Recruiting - verified March 2012 - Conditions: Osteoarthritis; Rheumatoid Arthritis; Ankylosing Spondylitis; Other Arthritic Conditions (e.g., Psoriatic Arthritis)
Intervention: Behavioral: painACTION: Arthritis
Sponsors: Inflexxion, Inc.; Inflexxion, Inc.
Recruiting - verified October 2011 - Condition: Retraction of Colostomy
Interventions: Drug: Morphine Sulfate; Drug: bupivacaine liposome extended-release injectable suspension
Sponsors: Pacira Pharmaceuticals, Inc; Pacira Pharmaceuticals, Inc; Registrat-Mapi
Recruiting - verified February 2012 - Condition: Retraction of Colostomy
Interventions: Drug: IV morphine sulfate; Drug: SKY0402 (bupivacaine liposome injectable suspension)
Sponsors: Pacira Pharmaceuticals, Inc; Pacira Pharmaceuticals, Inc; Registrat-Mapi
Recruiting - verified February 2012 - Condition: Bowel Obstruction
Interventions: Drug: IV Morphine Sulfate; Drug: SKY0402 (bupivacaine liposome injectable suspension)
Sponsors: Pacira Pharmaceuticals, Inc; Pacira Pharmaceuticals, Inc; Registrat-Mapi
Recruiting - verified April 2012 - Condition: Bowel Obstruction
Interventions: Drug: IV morphine sulfate; Drug: EXPAREL (bupivacaine liposome injectable suspension)
Sponsors: Pacira Pharmaceuticals, Inc; Pacira Pharmaceuticals, Inc; Registrat-Mapi
Recruiting - verified February 2012 - Condition: Bowel Obstruction
Interventions: Drug: IV morphine sulfate; Drug: SKY0402 (bupivacaine liposome extended-release injectable suspension)
Sponsors: Pacira Pharmaceuticals, Inc; Pacira Pharmaceuticals, Inc; Registrat-Mapi
Recruiting - verified January 2012 - Condition: Bowel Obstruction
Interventions: Drug: IV Morphine Sulfate; Drug: SKY0402 (bupivacaine liposome extended-release injectable suspension)
Sponsors: Pacira Pharmaceuticals, Inc; Pacira Pharmaceuticals, Inc; Registrat-Mapi
Recruiting - verified January 2012 - Condition: Bowel Obstruction
Interventions: Drug: morphine sulfate; Drug: bupivacaine liposome extended-release injectable suspension
Sponsors: Pacira Pharmaceuticals, Inc; Pacira Pharmaceuticals, Inc; Registrat-Mapi
Recruiting - verified January 2012 - Condition: Bowel Obstruction
Interventions: Drug: IV morphine sulfate; Drug: SKY0402 (bupivacaine liposome injectable suspension)
Sponsors: Pacira Pharmaceuticals, Inc; Pacira Pharmaceuticals, Inc; Registrat-Mapi
Recruiting - verified January 2012 - Condition: Multiple Myeloma
Interventions: Drug: Carfilzomib; Drug: Pomalidomide; Drug: Dexamethasone
Sponsors: Academic Myeloma Consortium; Academic Myeloma Consortium; CORE Science Solutions; Onyx Pharmaceuticals; Celgene Corporation
Recruiting - verified February 2012 - Conditions: CLL; SLL
Interventions: Drug: Ofatumumab; Drug: High-Dose Methylprednisolone; Drug: Alemtuzumab
Sponsors: Dana-Farber Cancer Institute; Dana-Farber Cancer Institute; National Comprehensive Cancer Network; GlaxoSmithKline
Recruiting - verified December 2011 - Condition: Lung Cancer
Interventions: Drug: DOTAP:Chol-fus1; Drug: Erlotinib; Drug: Dexamethasone; Drug: Diphenhydramine
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Convergen LifeSciences, Inc.
Not yet recruiting - verified March 2012 - Conditions: Uterine Fibroids; Uterine Artery Embolization
Interventions: Drug: pregabalin/celecoxib; Drug: pregabalin/placebo; Drug: celecoxib/placebo; Drug: Placebo group
Sponsors: Northwestern University; Northwestern University
Recruiting - verified March 2012 - Condition: Hereditary Angioedema
Intervention: Drug: Icatibant
Sponsors: Massachusetts General Hospital; Massachusetts General Hospital; Shire Human Genetic Therapies, Inc.
Recruiting - verified April 2012 - Condition: Crohn's Disease
Intervention: Drug: Entocort
Sponsors: AstraZeneca; AstraZeneca
Recruiting - verified February 2012 - Conditions: Lung Cancer; Head and Neck Cancer; Hearing Loss; Ototoxicity; Tinnitus; Neuropathy
Interventions: Drug: SPI-1005 Low Dose; Drug: SPI-1005 Middle dose; Drug: SPI-1005 High Dose; Drug: Placebo
Sponsors: Sound Pharmaceuticals, Incorporated; Sound Pharmaceuticals, Incorporated; VA Puget Sound Health Care System
Not yet recruiting - verified October 2011 - Condition: Eye Allergies
Interventions: Drug: Olopatadine hydrochloride 0.2%; Drug: Bepotastine besilate ophthalmic solution 1.5%
Sponsors: McCabe Vision Center; McCabe Vision Center
Recruiting - verified October 2011 - Condition: Interscalene Blockade in Elective Arthroscopic Rotator Cuff Repair
Interventions: Drug: Ropivacaine; Drug: Dexamethasone; Drug: Dexamethasone; Drug: Normal saline; Drug: Normal saline
Sponsors: Mayo Clinic; Mayo Clinic
Recruiting - verified May 2012 - Conditions: Retinal Vein Occlusion; Macular Edema
Interventions: Drug: Ozurdex; Drug: Ozurdex
Sponsors: Retina Macula Institute; Retina Macula Institute; Allergan
Recruiting - verified April 2012 - Condition: Stroke
Interventions: Drug: Anti-platelets and statin; Drug: alteplase; Procedure: intra arterial intervention
Sponsors: Jacobs Neurological Institute; Jacobs Neurological Institute; University at Buffalo Neurosurgery; Genentech
Recruiting - verified March 2012 - Condition: Cornea Transplant Recipients
Interventions: Drug: Prednisolone acetate; Drug: Fluorometholone
Sponsors: Price Vision Group; Price Vision Group
Recruiting - verified April 2012 - Conditions: Breast Neoplasms; Breast Cancer
Interventions: Drug: Taxane; Drug: Taxotere; Drug: Abraxane; Drug: Ixabepilone
Sponsors: The Methodist Hospital System; The Methodist Hospital System
Recruiting - verified September 2011 - Condition: Temporary Auditory Threshold Shift
Interventions: Drug: SPI-1005 Low dose; Drug: SPI-1005 Middle dose; Drug: SPI-1005 High dose; Drug: Placebo
Sponsors: Sound Pharmaceuticals, Incorporated; Sound Pharmaceuticals, Incorporated; University of Florida
Recruiting - verified October 2011 - Condition: Scleroderma
Interventions: Procedure: Rituximab sandwich regiment followed by SCT; Procedure: cyclophosphamide regiment followed by SCT
Sponsors: Northwestern University; Richard Burt, MD
Recruiting - verified April 2012 - Condition: Crohn's Disease
Intervention: Drug: Entocort
Sponsors: AstraZeneca; AstraZeneca
Recruiting - verified February 2012 - Condition: Bipolar Depression
Interventions: Drug: ESC + CBX; Drug: ESC + PBO.; Drug: ESC+CBX
Sponsors: Loyola University; Loyola University; Stanley Medical Research Institute
Recruiting - verified December 2011 - Condition: Asthma
Interventions: Drug: Symbicort pMDI; Drug: Symbicort pMDI; Drug: budesonide pMDI; Drug: budesonide pMDI
Sponsors: AstraZeneca; AstraZeneca
Recruiting - verified March 2012 - Condition: Lumbar Radiculopathy
Interventions: Other: Lumbar Transforaminal Epidural Corticosteroid Injection; Other: Physical Therapy; Other: Observation
Sponsors: Stanford University; Stanford University
Recruiting - verified September 2011 - Condition: Myeloma
Interventions: Drug: Panobinostat; Drug: Bortezomib; Drug: Lenalidomide; Drug: Dexamethasone; Behavioral: Symptom Questionnaire
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Novartis
Not yet recruiting - verified March 2012 - Condition: Waldenstrom's Macroglobulinemia
Interventions: Drug: Dexamethasone; Drug: Carfilzomib; Drug: Rituximab
Sponsors: Dana-Farber Cancer Institute; Dana-Farber Cancer Institute; Onyx Pharmaceuticals
Recruiting - verified November 2011 - Condition: Crohn's Disease
Intervention: Drug: Remicade
Sponsors: Mount Sinai School of Medicine; Shradha Agarwal; Prometheus Laboratories
Recruiting - verified December 2011 - Condition: Asthma
Interventions: Drug: Fluticasone furoate 50mcg; Drug: Fluticasone propionate 100mcg; Drug: Placebo
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified March 2012 - Condition: Asthma
Interventions: Drug: Fluticasone furoate 50mcg; Drug: Placebo
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified April 2012 - Condition: Activity/Exercise Induced Bronchospasm
Interventions: Drug: Fluticasone Furoate/Vilanterol Inhalation Powder; Drug: Fluticasone Propionate Inhalation Powder
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Not yet recruiting - verified October 2011 - Condition: Psoriasis
Interventions: Behavioral: Standard nurse education; Behavioral: Additional nurse education
Sponsors: Wake Forest University; Wake Forest University
Recruiting - verified September 2011 - Condition: Multiple Myeloma
Interventions: Drug: Cyclophosphamide; Drug: Velcade; Drug: Chloroquine
Sponsors: New York University School of Medicine; New York University School of Medicine; Millennium Pharmaceuticals, Inc.
Recruiting - verified April 2012 - Condition: Myeloma
Interventions: Drug: Pomalidomide; Drug: Dexamethasone; Drug: Cyclophosphamide
Sponsors: H. Lee Moffitt Cancer Center and Research Institute; H. Lee Moffitt Cancer Center and Research Institute; Celgene Corporation
Recruiting - verified May 2012 - Condition: Asthma
Interventions: Drug: Fluticasone/Salmeterol Diskus; Drug: Fluticasone/Salmeterol Diskus; Drug: Fluticasone Diskus
Sponsors: Johns Hopkins University; Johns Hopkins University; American Lung Association; GlaxoSmithKline
Recruiting - verified May 2012 - Condition: Bipolar Disorder Depression
Interventions: Drug: Minocycline; Drug: Aspirin; Drug: placebo
Sponsors: Laureate Institute for Brain Research, Inc.; Laureate Institute for Brain Research, Inc.; Stanley Medical Research Institute; University of Oklahoma
Recruiting - verified March 2012 - Condition: Post-surgical Dental Pain
Interventions: Drug: PF-04531083; Other: Placebo; Drug: PF-04531083; Other: Placebo; Drug: Ibuprofen; Other: Placebo; Other: Placebo; Other: Placebo
Sponsors: Pfizer; Pfizer
Recruiting - verified April 2012 - Condition: Asthma
Interventions: Biological: Omalizumab; Drug: Fluticasone; Other: Placebo
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified February 2012 - Condition: Acne Vulgaris
Interventions: Drug: Fixed Combination dapsone/adapalene Formulation A Gel; Drug: Fixed Combination dapsone/adapalene Formulation B Gel; Drug: dapsone 5% gel; Drug: adapalene 0.3% gel
Sponsors: Allergan; Allergan
Not yet recruiting - verified May 2012 - Condition: Leukemia
Interventions: Drug: Cyclophosphamide; Drug: Mesna; Drug: Doxorubicin; Drug: Vincristine; Drug: Dexamethasone; Drug: Ponatinib; Drug: G-CSF (Filgrastim); Drug: Rituximab; Drug: Methotrexate; Drug: Cytarabine; Drug: Solu-medrol ( Methyl Prednisolone); Drug: Citrovorum (Leucovorin); Drug: Prednisone; Drug: Pegfilgrastim (Neulasta)
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Ariad Pharmaceuticals
Recruiting - verified May 2012 - Conditions: Obesity; Hyperandrogenemia; Polycystic Ovary Syndrome
Interventions: Drug: Metformin; Drug: Dexamethasone; Drug: Cosyntropin; Drug: r-hCG (Ovidrel)
Sponsors: University of Virginia; University of Virginia
Not yet recruiting - verified August 2011 - Conditions: Hyperandrogenemia; Obesity; Polycystic Ovary Syndrome
Interventions: Drug: Hydrocortisone; Drug: dexamethasone; Drug: Cosyntropin; Drug: r-hCG (Ovidrel)
Sponsors: University of Virginia; University of Virginia
Not yet recruiting - verified August 2011 - Conditions: Obesity; Hyperandrogenemia; Polycystic Ovary Syndrome
Interventions: Drug: Spironolactone; Drug: Dexamethasone; Drug: Cosyntropin; Drug: r-hCG (Ovidrel)
Sponsors: University of Virginia; University of Virginia
Not yet recruiting - verified August 2011 - Condition: Breast Cancer
Interventions: Other: questionnaire administration; Drug: fluocinonide cream; Procedure: management of therapy complications
Sponsors: OHSU Knight Cancer Institute; OHSU Knight Cancer Institute; National Cancer Institute (NCI)
Recruiting - verified April 2012 - Conditions: Hyperandrogenemia; Obesity; Polycystic Ovary Syndrome
Interventions: Drug: Hydrocortisone; Drug: dexamethasone; Drug: Cosyntropin (ACTH)
Sponsors: University of Virginia; University of Virginia
Not yet recruiting - verified August 2011 - Conditions: Hyperandrogenemia; Obesity; Polycystic Ovary Syndrome
Interventions: Drug: Leuprolide; Drug: Dexamethasone; Drug: recombinant human chorionic gonadotropin
Sponsors: University of Virginia; University of Virginia
Not yet recruiting - verified August 2011 - Conditions: Hyperandrogenemia; Polycystic Ovary Syndrome; Obesity
Interventions: Drug: Dexamethasone; Drug: Cortrosyn
Sponsors: University of Virginia; University of Virginia; Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); University of California, San Diego
Recruiting - verified August 2011 - Condition: Lymphoblastic Lymphoma
Interventions: Drug: prednisone, vincristine, daunorubicin, PEG-asparaginase, methotrexate, hydrocortisone, cytarabine (IT-MH)A treatment, cyclophosphamide, cytarabine, thioguanine; Drug: PEG- asparaginase, High-Dose Methotrexate (HD-MTX) and Mercaptopurine; Drug: Dexamethasone, Doxorubicin; Vincristine; Mercaptopurine; PEG- Asparaginase, Cyclophosphamide, and Cytarabine; Drug: dexamethasone, cytarabine, etoposide, pegaspargase, clofarabine, cyclophosphamide; Drug: Intrathecal chemotherapy
Sponsors: St. Jude Children's Research Hospital; St. Jude Children's Research Hospital; National University, Singapore
Recruiting - verified April 2012 - Conditions: Polycystic Ovary Syndrome; Obesity; Hyperandrogenism
Interventions: Drug: Dexamethasone; Drug: r-hCG (Ovidrel)
Sponsors: University of Virginia; University of Virginia; University of California, San Diego
Recruiting - verified August 2011 - Condition: Multiple Sclerosis
Interventions: Drug: diclofenac sodium topical gel; Other: Placebo
Sponsors: Brown, Theodore R., M.D., MPH; Brown, Theodore R., M.D., MPH; Teva Neuroscience, Inc.
Recruiting - verified October 2011 - Condition: Multiple Myeloma
Interventions: Drug: GSK2110183; Drug: Bortezomib; Drug: Dexamethasone
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified February 2012 - Conditions: Lymphoma, Diffuse Large-Cell B-cell; Diffuse, Large B-cell Lymphoma; Lymphoma, Diffuse Large-Cell; Large-Cell Lymphoma, Diffuse
Interventions: Drug: MLN4924; Drug: Etoposide; Drug: Prednisone; Drug: Vincristine; Drug: Cyclophosphamide; Drug: Doxorubicin; Drug: Rituximab; Drug: Filgrastim
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Not yet recruiting - verified April 2012 - Condition: Lymphoma, B-Cell
Interventions: Drug: RO50722759; Drug: cyclophosphamide; Drug: doxorubicin; Drug: vincristine; Drug: prednisone
Sponsors: Genentech; Genentech
Recruiting - verified October 2011 - Conditions: Thyroid Cancer; Hashimotos Thyroiditis
Intervention:
Sponsors: The University of Texas, Galveston; The University of Texas, Galveston
Recruiting - verified September 2011 - Conditions: Advanced Malignancies; Carcinoma, Non-Small-Cell Lung; Anaplastic Large Cell Lymphoma; Diffuse Large Cell Lymphoma; Inflammatory Myofibroblastic Tumors
Intervention: Drug: AP26113
Sponsors: Ariad Pharmaceuticals; Ariad Pharmaceuticals
Recruiting - verified April 2012 - Condition: Lymphoma
Interventions: Biological: rituximab; Drug: bendamustine hydrochloride; Drug: cyclophosphamide; Drug: cytarabine; Drug: dexamethasone; Drug: doxorubicin hydrochloride; Drug: leucovorin calcium; Drug: methotrexate; Drug: vincristine sulfate
Sponsors: National Cancer Institute (NCI); Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Condition: Multiple Myeloma
Interventions: Drug: proteasome inhibitor MLN9708; Drug: dexamethasone
Sponsors: Mayo Clinic; Mayo Clinic; National Cancer Institute (NCI)
Recruiting - verified March 2012 - Condition: Leukemia
Interventions: Drug: ATRA; Drug: ATO; Drug: GO (Gemtuzumab ozogamicin); Drug: Methylprednisolone
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Pfizer
Recruiting - verified March 2012 - Condition: Blepharitis
Interventions: Drug: ISV-502; Drug: Azasite; Drug: Dexamethasone; Other: Vehicle
Sponsors: InSite Vision; InSite Vision
Recruiting - verified April 2012 - Conditions: Cognitive/Functional Effects; Leukemia; Neurotoxicity; Pain; Therapy-related Toxicity
Interventions: Drug: clofarabine; Drug: cyclophosphamide; Drug: cytarabine; Drug: doxorubicin hydrochloride; Drug: etoposide; Drug: hydrocortisone sodium succinate; Drug: leucovorin calcium; Drug: mercaptopurine; Drug: methotrexate; Drug: pegaspargase; Drug: prednisone; Drug: thioguanine; Drug: vincristine sulfate; Radiation: selective external radiation therapy
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Condition: Pneumonia
Intervention:
Sponsors: Washington University School of Medicine; Washington University School of Medicine; Barnes-Jewish Hospital Foundation
Recruiting - verified July 2011 - Condition: Multiple Myeloma
Interventions: Drug: Carfilzomib; Drug: Lenalidomide; Drug: Dexamethasone
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI); Celgene Corporation; Onyx Therapeutics, Inc.
Recruiting - verified July 2011 - Condition: Pulmonary Disease, Chronic Obstructive
Interventions: Drug: Tetrahydrobiopterin (BH4); Drug: non-acetylated salicylate; Dietary Supplement: High Fat Meal; Drug: L-NMMA; Dietary Supplement: Antioxidant Cocktail
Sponsors: Georgia Health Sciences University; Georgia Health Sciences University; American Heart Association
Recruiting - verified July 2011 - Conditions: Leukemia; Lymphoma
Interventions: Drug: dexamethasone; Drug: methotrexate; Drug: mitoxantrone hydrochloride; Drug: pegaspargase; Drug: temsirolimus; Drug: vincristine sulfate; Other: laboratory biomarker analysis; Other: pharmacological study
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Conditions: Prostate Neoplasms; Prostate Cancer
Interventions: Drug: Cohort 4; Drug: Cohort 3; Drug: Cohort 2; Drug: Cohort 1
Sponsors: Cougar Biotechnology, Inc.; Cougar Biotechnology, Inc.
Recruiting - verified May 2012 - Conditions: Epiretinal Membrane; Macular Edema
Intervention: Drug: Dexamethasone Intravtireal Implant
Sponsors: Barnes Retina Institute; Barnes Retina Institute; Allergan
Recruiting - verified April 2012 - Condition: CAD
Intervention:
Sponsors: Creighton University; Creighton University
Recruiting - verified January 2012 - Condition: Myeloma
Interventions: Drug: Hydroxychloroquine; Drug: Rapamycin
Sponsors: Abramson Cancer Center of the University of Pennsylvania; Abramson Cancer Center of the University of Pennsylvania
Recruiting - verified May 2012 - Condition: Multiple Myeloma
Interventions: Drug: Lenalidomide; Drug: Dexamethasone; Drug: Dexamethasone; Drug: Dexamethasone; Biological: Elotuzumab (BMS-901608; HuLuc63); Drug: Lenalidomide; Drug: Lenalidomide
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb; Abbott Biotherapeutics Corp.
Recruiting - verified October 2011 - Conditions: Acute Urinary Tract Infection; Urinary Tract Infection
Interventions: Drug: Placebo; Drug: Dexamethasone
Sponsors: University of Pittsburgh; University of Pittsburgh; National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Recruiting - verified January 2012 - Conditions: KSHV Inflammatory Cytokine Syndrome (KICS); KSHV; HHV-8
Interventions: Drug: Zidovudine/Valgancyclovir; Drug: Rituximab/Liposoma Doxorubicin
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified May 2012 - Condition: Hereditary Angioedema
Intervention: Drug: icatibant
Sponsors: Shire Human Genetic Therapies, Inc.; Shire Human Genetic Therapies, Inc.
Recruiting - verified May 2012 - Condition: Atopic Dermatitis
Interventions: Behavioral: Weekly Internet survey; Drug: Topical Triamcinolone
Sponsors: Wake Forest University; Wake Forest University
Recruiting - verified June 2011 - Condition: Asthma
Intervention: Drug: Flovent Diskus, Advair Diskus, Ventolin HFA, cetirizine, Flonase Nasal Spray, Singulair
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified August 2011 - Condition: Multiple Myeloma
Intervention: Drug: MLN9708 + Lenalidomide + Dexamethasone
Sponsors: Millennium Pharmaceuticals, Inc.; Millennium Pharmaceuticals, Inc.
Recruiting - verified May 2012 - Conditions: Light Chain Deposition Disease (LCDD or MIDD); Light Chain and Heavy Chain Deposition Disease (LHCDD or MIDD); Monoclonal Immunoglobulin Deposition Disease (MIDD); Amyloidosis
Intervention: Drug: Bortezomib/Dexamethasone (BD), Followed By Autologous STC & Maintenance Bortezomib/Dexamethasone
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center; Millennium Pharmaceuticals, Inc.
Recruiting - verified May 2012 - Conditions: Post Infective IBS-D; Irritable Bowel Syndrome With Diarrhea
Intervention: Drug: Mesalamine
Sponsors: University of Utah; University of Utah; Shire Human Genetic Therapies, Inc.
Recruiting - verified August 2011 - Condition: Inflammatory Response
Interventions: Drug: Ibuprofen; Drug: Placebo/Saline solution
Sponsors: New York University School of Medicine; New York University School of Medicine
Recruiting - verified June 2011 - Condition: Breast Cancer
Intervention: Other: Diclofenac epolamine patch
Sponsors: Northwestern University; Northwestern University
Recruiting - verified May 2012 - Condition: Knee Osteoarthritis
Intervention: Drug: Voltaren
Sponsors: Brigham and Women's Hospital; Brigham and Women's Hospital; Endo Pharmaceuticals
Recruiting - verified June 2011 - Conditions: Age-associated Cognitive Impairment; Mild Cognitive Impairment (MCI)
Interventions: Dietary Supplement: Curcumin; Dietary Supplement: Sugar pill
Sponsors: University of California, Los Angeles; University of California, Los Angeles
Recruiting - verified April 2012 - Conditions: Cognitive/Functional Effects; Fatigue; Lymphoma; Neurotoxicity; Therapy-related Toxicity
Interventions: Biological: rituximab; Drug: bortezomib; Drug: dexamethasone; Drug: temsirolimus
Sponsors: National Cancer Institute (NCI); Eastern Cooperative Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Conditions: Metastatic ER+ Her2- Breast Cancer; Postmenopausal
Interventions: Drug: Exemestane; Drug: Abiraterone acetate + Prednisone/ Prednisolone + Exemestane; Drug: Abiraterone acetate + Prednisone or Prednisolone
Sponsors: Janssen Research & Development, LLC; Janssen Research & Development, LLC
Recruiting - verified May 2012 - Condition: Relapsed Multiple Myeloma
Interventions: Drug: Lenalidomide 15mg; Drug: Lenalidomide 25mg
Sponsors: Boston VA Research Institute, Inc.; Boston VA Research Institute, Inc.; Celgene Corporation; Kansas City Veteran Affairs Medical Center; VA Pittsburgh Healthcare System; VA Greater Los Angeles Healthcare System; Michael Debakey Veterans Affairs Medical Center; Edward Hines Jr. VA Hospital
Recruiting - verified September 2011 - Condition: Prostate Cancer
Interventions: Drug: Abiraterone acetate; Drug: Dutasteride; Drug: Prednisone
Sponsors: Dana-Farber Cancer Institute; Mary-Ellen Taplin, MD
Recruiting - verified February 2012 - Conditions: Osteoarthritis; Chronic Pain
Intervention: Drug: duloxetine, diclofenac
Sponsors: University of Michigan; University of Michigan; National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS); National Center for Research Resources (NCRR); Merck; Nuvo Research Inc.
Recruiting - verified March 2012 - Condition: Pain, Postoperative
Intervention: Drug: Ketolorac
Sponsors: The Cleveland Clinic; The Cleveland Clinic
Not yet recruiting - verified February 2012 - Condition: Myeloproliferative Diseases
Interventions: Drug: Ruxolitinib; Drug: Lenalidomide; Drug: Prednisone
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Incyte Corporation
Recruiting - verified March 2012 - Condition: Rheumatoid Arthritis
Interventions: Drug: PF-04171327; Drug: PF-04171327; Drug: PF-04171327; Drug: PF-04171327; Drug: prednisone; Other: prednisone; Other: placebo
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2012 - Condition: Rheumatoid Arthritis
Interventions: Drug: BMS-945429 Placebo; Biological: BMS-945429; Biological: BMS-945429; Biological: BMS-945429; Biological: BMS-945429; Drug: Methotrexate; Drug: Methotrexate; Drug: Methotrexate Placebo; Drug: Methotrexate; Drug: Adalimumab Placebo; Drug: Adalimumab
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Recruiting - verified January 2012 - Condition: Multiple Myeloma
Intervention: Drug: Tadalafil, Cialis
Sponsors: Sidney Kimmel Comprehensive Cancer Center; Sidney Kimmel Comprehensive Cancer Center
Recruiting - verified January 2012 - Condition: Prostate Cancer
Interventions: Drug: Pazopanib; Drug: Docetaxel; Drug: Pazopanib; Drug: Prednisone
Sponsors: Duke University; Duke University; GlaxoSmithKline
Recruiting - verified July 2011 - Condition: Myeloma
Interventions: Drug: Arry-520; Drug: Carfilzomib; Drug: Dexamethasone; Drug: Filgrastim
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Array BioPharma; Onyx Therapeutics, Inc.
Recruiting - verified February 2012 - Condition: Psoriasis
Intervention: Drug: RA-18C3
Sponsors: XBiotech, Inc.; XBiotech, Inc.
Recruiting - verified April 2012 - Conditions: Leukemia; Acute Lymphoblastic Leukemia
Interventions: Drug: Inotuzumab Ozogamycin; Drug: Rituximab; Drug: Cyclophosphamide; Drug: Mesna; Drug: Vincristine; Drug: Dexamethasone; Drug: Pegfilgrastim; Drug: Methotrexate; Drug: Ara-C; Drug: Inotuzumab Ozogamycin
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Pfizer
Recruiting - verified April 2012 - Condition: Chemotherapy-induced Nausea and Vomiting
Intervention: Drug: Palonosetron, ondansetron, dexamethasone
Sponsors: Northside Hospital, Inc.; Northside Hospital, Inc.; Blood and Marrow Transplant Group of Georgia
Recruiting - verified March 2012 - Condition: Rheumatoid Arthritis
Interventions: Drug: Prednisolone; Drug: dipyridamole; Drug: Prednisone; Drug: prednisolone-dipyridamole; Other: placebo
Sponsors: Zalicus; Zalicus
Recruiting - verified June 2011 - Condition: Idiopathic Pulmonary Fibrosis
Interventions: Drug: Pirfenidone; Drug: Placebo
Sponsors: InterMune; InterMune
Recruiting - verified June 2011 - Condition: Chemotherapy-Induced Nausea and Vomiting
Interventions: Drug: Oral palonosetron; Drug: I.V. palonosetron
Sponsors: Helsinn Healthcare SA; Helsinn Healthcare SA; Parexel
Recruiting - verified December 2011 - Condition: Chronic Kidney Disease
Intervention:
Sponsors: North Shore Long Island Jewish Health System; Staten Island University Hospital
Recruiting - verified April 2011 - Condition: Leukemia
Interventions: Drug: Cyclophosphamide; Drug: Mesna; Drug: Doxorubicin; Drug: Vincristine; Drug: Dexamethasone; Drug: Ofatumumab; Drug: Methotrexate; Drug: Cytarabine
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; GlaxoSmithKline
Recruiting - verified May 2012 - Condition: Pain
Interventions: Drug: Ketorolac; Drug: Ibuprofen
Sponsors: Planned Parenthood League of Massachusetts; Planned Parenthood League of Massachusetts; Society of Family Planning
Recruiting - verified May 2012 - Condition: Lymphoma
Interventions: Biological: rituximab; Drug: cyclophosphamide; Drug: doxorubicin hydrochloride; Drug: prednisone; Drug: vincristine sulfate; Other: R-CHOP regimen; Other: laboratory biomarker analysis; Radiation: fludeoxyglucose F 18; Radiation: selective external radiation therapy; Radiation: yttrium Y 90 ibritumomab tiuxetan
Sponsors: National Cancer Institute (NCI); Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Condition: Multiple Myeloma
Interventions: Drug: Amrubicin; Drug: Lenalidomide; Drug: Dexamethasone; Drug: Aspirin
Sponsors: Stanford University; Stanford University; Celgene Corporation
Recruiting - verified October 2011 - Condition: Juvenile Idiopathic Arthritis
Interventions: Drug: naproxen; Drug: esomeprazole
Sponsors: AstraZeneca; AstraZeneca
Recruiting - verified June 2011 - Condition: Acute Gouty Arthritis
Interventions: Drug: Canakinumab pre-filled syringe; Drug: Canakinumab lyophilized cake; Drug: Triamcinolone Acetonide
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified April 2012 - Condition: Impaired Glucose Tolerance
Interventions: Dietary Supplement: resveratrol; Drug: Placebo
Sponsors: Albert Einstein College of Medicine of Yeshiva University; Albert Einstein College of Medicine of Yeshiva University; American Diabetes Association
Recruiting - verified June 2011 - Condition: Polymyalgia Rheumatica (PMR)
Intervention: Drug: Tocilizumab
Sponsors: Hospital for Special Surgery, New York; Hospital for Special Surgery, New York; Genentech
Recruiting - verified January 2012 - Condition: Multiple Myeloma
Interventions: Biological: Anti-CXCR4 (BMS-936564); Biological: Lenalidomide; Biological: Dexamethasone; Biological: Anti-CXCR4 (BMS-936564); Biological: Bortezomib; Biological: Dexamethasone
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Recruiting - verified August 2011 - Conditions: Proctitis; Proctosigmoiditis
Intervention: Drug: Budesonide Foam
Sponsors: Salix Pharmaceuticals; Salix Pharmaceuticals
Recruiting - verified July 2011 - Condition: Rheumatoid Arthritis
Interventions: Drug: Secukinumab (75 mg); Drug: Secukinumab (150 mg); Drug: Placebo
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified May 2012 - Conditions: Obesity; Hyperlipidemia; Insulin Resistance; Hypertension
Interventions: Dietary Supplement: Liposomal Glutathione Dietary Supplement; Dietary Supplement: N-Acetyl cysteine Dietary Supplement; Other: Placebo products for Glutathione and N-Acetylcysteine
Sponsors: Stanford University; Stanford University
Recruiting - verified March 2012 - Condition: Breast Cancer
Interventions: Drug: Celecoxib; Drug: Placebo; Drug: Cholecalciferol
Sponsors: University of North Dakota; University of North Dakota; Department of Defense
Recruiting - verified August 2011 - Conditions: Sarcoma; Melanoma; Epithelial Malignancies; Pleural Malignancy
Interventions: Biological: Epigenetically Modified Autologous Tumor; Drug: Cyclophosphamide; Drug: Celecoxib
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified December 2011 - Condition: Rheumatoid Arthritis
Interventions: Drug: Open Label Drug Certolizumab Pegol (CZP); Procedure: Arthroscopic synovial tissue biopsy
Sponsors: Arthritis Treatment Center, Maryland; Nathan Wei, MD, FACP, FACR:; University of California, San Diego
Recruiting - verified September 2011 - Conditions: Infant, Newborn; Infant, Small for Gestational Age; Infant, Very Low Birth Weight; Infant, Premature; Bronchopulmonary Dysplasia
Interventions: Drug: Hydrocortisone; Drug: Placebo
Sponsors: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); National Center for Research Resources (NCRR)
Recruiting - verified August 2011 - Condition: Chemotherapy-Induced Nausea and Vomiting
Interventions: Drug: Netupitant and Palonosetron; Drug: Palonosetron
Sponsors: Helsinn Healthcare SA; Helsinn Healthcare SA; Parexel
Recruiting - verified December 2011 - Condition: Diabetic Macular Edema
Interventions: Drug: nepafenac 0.1% drops; Other: Nepafenac Vehicle
Sponsors: Diabetic Retinopathy Clinical Research Network; Diabetic Retinopathy Clinical Research Network; National Eye Institute (NEI)
Recruiting - verified November 2011 - Condition: Pain
Intervention: Drug: Intravenous ibuprofen
Sponsors: Cumberland Pharmaceuticals; Cumberland Pharmaceuticals
Recruiting - verified April 2012 - Conditions: Pain; Fever
Intervention: Drug: Intravenous ibuprofen
Sponsors: Cumberland Pharmaceuticals; Cumberland Pharmaceuticals
Recruiting - verified May 2012 - Condition: Multiple Myeloma
Interventions: Drug: Lenalidomide; Drug: Dexamethasone; Drug: Dexamethasone; Drug: Dexamethasone; Drug: Dexamethasone; Biological: Elotuzumab (BMS-901608; HuLuc63); Biological: Elotuzumab (BMS-901608; HuLuc63)
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb; Abbott Biotherapeutics Corp.
Recruiting - verified October 2011 - Condition: Lymphoma
Interventions: Biological: rituximab; Drug: cyclophosphamide; Drug: doxorubicin hydrochloride; Drug: everolimus; Drug: prednisone; Drug: vincristine sulfate; Other: R-CHOP regimen; Other: laboratory biomarker analysis
Sponsors: National Cancer Institute (NCI); North Central Cancer Treatment Group; National Cancer Institute (NCI)
Recruiting - verified March 2012 - Condition: Cardiovascular Disease, Rheumatoid Arthritis
Interventions: Drug: tocilizumab [RoActemra/Actemra]; Drug: etanercept
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified March 2012 - Condition: Tonsillectomy
Interventions: Drug: Intravenous ibuprofen; Other: Normal Saline
Sponsors: Cumberland Pharmaceuticals; Cumberland Pharmaceuticals
Recruiting - verified January 2012 - Condition: Multiple Myeloma
Interventions: Drug: MLN9708 plus Melphalan and Prednisone; Drug: MLN9708 plus Melphalan and Prednisone
Sponsors: Millennium Pharmaceuticals, Inc.; Millennium Pharmaceuticals, Inc.
Recruiting - verified May 2012 - Condition: Myeloma
Intervention: Drug: Simvastatin,Zoledronic Acid,Bortezomib,Bendamustine,Methylprednisolone.
Sponsors: James Graham Brown Cancer Center; Geoffry Herzig, MD
Recruiting - verified April 2012 - Condition: Pulmonary Disease, Chronic Obstructive
Interventions: Drug: Fluticasone Furoate/Vilanterol; Drug: Vilanterol; Drug: Placebo
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified April 2012 - Condition: Precursor Cell Lymphoblastic Leukemia-Lymphoma
Intervention: Drug: Filgrastim, Ifosfamide, Etoposide, Dexamethasone, Mesna
Sponsors: Washington University School of Medicine; Washington University School of Medicine
Recruiting - verified October 2011 - Condition: Acute Lymphoblastic Leukemia
Interventions: Drug: Metformin; Drug: Vincristine; Drug: Dexamethasone; Drug: PEG-asparaginase; Drug: Doxorubicin; Drug: Intrathecal chemotherapy
Sponsors: H. Lee Moffitt Cancer Center and Research Institute; H. Lee Moffitt Cancer Center and Research Institute; Pediatric Cancer Foundation
Recruiting - verified April 2012 - Conditions: Anaplastic Large Cell Lymphoma; Angioimmunoblastic T-cell Lymphoma; Hepatosplenic T-cell Lymphoma; Peripheral T-cell Lymphoma
Interventions: Drug: prednisone; Drug: cyclophosphamide; Drug: etoposide; Drug: vincristine sulfate; Drug: pralatrexate; Other: laboratory biomarker analysis; Genetic: comparative genomic hybridization; Genetic: gene expression analysis; Genetic: nucleic acid sequencing; Genetic: mutation analysis; Other: immunohistochemistry staining method; Genetic: microarray analysis; Genetic: RNA analysis
Sponsors: University of Nebraska; University of Nebraska; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Condition: Pulmonary Disease, Chronic Obstructive
Interventions: Drug: PH-797804; Drug: Placebo
Sponsors: Pfizer; Pfizer
Recruiting - verified April 2012 - Condition: Lymphoma
Interventions: Radiation: Radiation; Drug: Cyclophosphamide; Drug: Doxorubicin; Drug: Vincristine; Drug: Prednisone
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified April 2012 - Condition: Menstrual Migraine
Interventions: Drug: sumatriptan/naproxen sodium; Drug: placebo
Sponsors: Cady, Roger, M.D.; Cady, Roger, M.D.; GlaxoSmithKline
Recruiting - verified February 2012 - Condition: Leukemia
Interventions: Drug: Rituximab; Drug: Imatinib; Drug: Cyclophosphamide; Drug: Doxorubicin; Drug: Mesna; Drug: VSLI; Drug: Solu-Medrol; Drug: Methotrexate; Drug: Ara-C; Drug: G-CSF; Drug: Pegfilgrastim; Drug: Dexamethasone
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Talon Therapeutics, Inc
Not yet recruiting - verified May 2012 - Condition: Psoriasis
Intervention: Drug: Adalimumab
Sponsors: University of North Carolina, Chapel Hill; University of North Carolina, Chapel Hill; Abbott
Recruiting - verified September 2011 - Condition: Acute Kidney Injury
Interventions: Drug: ATG; Drug: Rituximab; Drug: Methylprednisolone; Drug: Diphenhydramine; Drug: Acetaminophen; Drug: Tacrolimus; Drug: Sirolimus; Drug: Hydrocortisone; Drug: Prednisone
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); National Institute of Allergy and Infectious Diseases (NIAID); Immune Tolerance Network (ITN)
Recruiting - verified August 2011 - Conditions: Sjogren's Syndrome; Xerostomia
Intervention: Drug: Dexamethasone
Sponsors: National Institutes of Health Clinical Center (CC); National Institute of Dental and Craniofacial Research (NIDCR)
Recruiting - verified November 2011 - Condition: Rheumatoid Arthritis
Intervention: Drug: etanercept
Sponsors: Amgen; Amgen
Recruiting - verified March 2012 - Conditions: Polymyalgia Rheumatica; Inflammatory Diseases
Interventions: Drug: AIN457; Drug: ACZ885 (canakinumab); Drug: Prednisone
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified April 2012 - Condition: Acute Lymphoblastic Leukemia
Interventions: Drug: Bortezomib; Drug: Vorinostat; Drug: Dexamethasone; Drug: Methotrexate; Drug: Imatinib mesylate
Sponsors: Masonic Cancer Center, University of Minnesota; Masonic Cancer Center, University of Minnesota; Millennium Pharmaceuticals, Inc.
Recruiting - verified January 2012 - Condition: Metastatic Colorectal Cancer
Interventions: Drug: panitumumab; Drug: Randomization to No Panitumumab
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center; Amgen
Recruiting - verified March 2012 - Conditions: Prostate Cancer; Prostatic Neoplasm
Intervention: Drug: abiraterone acetate in combination with prednisone
Sponsors: Janssen Biotech, Inc.; Janssen Biotech, Inc.
Recruiting - verified May 2012 - Condition: Prostate Cancer
Interventions: Drug: Cabazitaxel (XRP6258); Drug: Docetaxel (XRP6976); Drug: Prednisone
Sponsors: Sanofi-Aventis; Sanofi-Aventis
Recruiting - verified April 2012 - Condition: Prostate Cancer
Interventions: Drug: Cabazitaxel (XRP6258); Drug: Prednisone
Sponsors: Sanofi-Aventis; Sanofi-Aventis
Recruiting - verified May 2012 - Condition: Low Back Pain
Interventions: Other: Medical Care; Other: Dual Care; Other: Shared Care
Sponsors: Palmer College of Chiropractic; Palmer College of Chiropractic; Health Resources and Services Administration (HRSA); Genesis Family Medical Center; University of Iowa; Thomas Jefferson University
Recruiting - verified January 2012 - Condition: Bronchiolitis Obliterans
Interventions: Drug: fluticasone propionate; Drug: montelukast sodium; Procedure: pulmonary function testing; Other: questionnaire administration; Procedure: quality-of-life assessment; Other: laboratory biomarker analysis; Genetic: protein analysis; Drug: azithromycin
Sponsors: Fred Hutchinson Cancer Research Center; Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium; National Cancer Institute (NCI)
Recruiting - verified March 2012 - Condition: Acute Sore Throat
Intervention: Device: Ear Acupuncture
Sponsors: Mike O'Callaghan Federal Hospital; Mike O'Callaghan Federal Hospital
Recruiting - verified April 2012 - Condition: Multiple Myeloma
Intervention: Drug: ACY-1215
Sponsors: Acetylon Pharmaceuticals Incorporated; Acetylon Pharmaceuticals Incorporated; The Leukemia and Lymphoma Society
Recruiting - verified April 2012 - Condition: Prostate CA
Interventions: Drug: Dexamethasone; Procedure: TAP block
Sponsors: Steward St. Elizabeth's Medical Center of Boston, Inc.; Steward St. Elizabeth's Medical Center of Boston, Inc.
Recruiting - verified February 2011 - Condition: Interstitial Cystitis
Interventions: Drug: Adalimumab; Other: inactive drug
Sponsors: ICStudy, LLC; ICStudy, LLC; Abbott
Recruiting - verified May 2012 - Condition: Multiple Myeloma
Intervention: Drug: Vorinostat, Lenalidomide, Carfilzomib, Dexamethasone
Sponsors: Hackensack University Medical Center; Hackensack University Medical Center
Recruiting - verified December 2011 - Conditions: Cortisol Resistance; Negative Feedback; ACTH; Mineralcorticoid; Glucocorticoid
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Recruiting - verified November 2011 - Condition: Colon Cancer
Interventions: Dietary Supplement: curcumin; Dietary Supplement: Curcumin conjugated with plant exosomes; Other: No intervention
Sponsors: James Graham Brown Cancer Center; James Graham Brown Cancer Center
Recruiting - verified September 2011 - Conditions: Leukemia; Lymphoma; Neuroblastoma; Sarcoma; Desmoplastic Small Round Cell Tumor
Interventions: Drug: Melphalan; Drug: Fludarabine; Drug: Cyclophosphamide; Drug: Cytarabine; Drug: Prednisone; Drug: Vincristine; Drug: Doxorubicin; Drug: Etoposide; Drug: Filgrastim; Biological: NK-DLI Infusions
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified March 2012 - Condition: Rheumatoid Arthritis
Interventions: Drug: tocilizumab [RoActemra/Actemra]; Drug: adalimumab; Drug: Placebo; Drug: Placebo; Drug: methotrexate; Drug: folate
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified April 2012 - Condition: Community Acquired Respiratory Disease Syndrome
Intervention: Drug: Methylprednisolone
Sponsors: Department of Veterans Affairs; Department of Veterans Affairs
Recruiting - verified April 2012 - Conditions: Immunosuppression; Healthy; Healthy Subjects
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified November 2011 - Conditions: Postmenopausal Osteoporosis; Rheumatoid Arthritis
Interventions: Drug: Etanercept; Drug: Denosumab
Sponsors: Amgen; Amgen
Recruiting - verified November 2011 - Condition: Rosacea
Interventions: Drug: Doxycycline; Other: Placebo
Sponsors: Galderma Laboratories, L.P.; Galderma Laboratories, L.P.
Recruiting - verified February 2012 - Condition: Patients Undergoing Repeat Peripheral Artery Revascularization
Intervention: Drug: CV-18C3
Sponsors: XBiotech, Inc.; XBiotech, Inc.
Recruiting - verified May 2012 - A Comparison of 0.5% Loteprednol Etabonate Versus 1% Prednisolone Acetate Following Cataract SurgeryCondition: Intraocular Inflammation
Intervention:
Sponsors: Associated Eye Care, Minnesota; Associated Eye Care, Minnesota; Bausch & Lomb, Inc.
Recruiting - verified June 2011 - Conditions: Acute Respiratory Distress Syndrome (ARDS); Acute Lung Injury (ALI)
Interventions: Drug: methylprednisolone; Drug: Normal Saline (0.9%)
Sponsors: University of Tennessee; University of Tennessee
Recruiting - verified July 2011 - Condition: Pain
Interventions: Drug: Fentanyl; Drug: Fentanyl; Drug: Oxycodone/acetaminophen; Drug: oxycodone/acetaminophen
Sponsors: University of Oklahoma; Stephen Thomas; University of Oklahoma
Recruiting - verified February 2012 - Condition: Perennial Allergic Rhinitis
Interventions: Drug: Budesonide; Drug: Placebo
Sponsors: University of Chicago; University of Chicago; MedInvent, LLC
Recruiting - verified September 2011 - Condition: Multiple Myeloma
Interventions: Drug: Curcumin; Other: Placebo
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; National Institutes of Health (NIH)
Not yet recruiting - verified April 2012 - Conditions: Laceration; Pain
Interventions: Drug: Ibuprofen; Drug: Oxycodone; Other: Placebo
Sponsors: Children's Hospitals and Clinics of Minnesota; Children's Hospitals and Clinics of Minnesota
Not yet recruiting - verified November 2011 - Condition: Hepatocellular Carcinoma
Interventions: Drug: Sorafenib; Drug: VT-122 (propranolol plus etodolac); Drug: Placebo
Sponsors: Vicus Therapeutics; Vicus Therapeutics
Recruiting - verified May 2012 - Condition: Neoplasm Metastases
Interventions: Drug: Sequence 1; Drug: Sequence 2; Drug: Sequence 1; Drug: Sequence 2
Sponsors: Janssen Research & Development, LLC; Janssen Research & Development, LLC
Recruiting - verified May 2012 - Conditions: Neoplasm Metastases; Hepatic Insufficiency
Interventions: Drug: Hepatic dysfunction group; Drug: Control group
Sponsors: Janssen Research & Development, LLC; Janssen Research & Development, LLC; PharmaMar
Recruiting - verified May 2012 - Condition: Crohn's Disease
Intervention: Drug: Infliximab
Sponsors: Oregon Health and Science University; Oregon Health and Science University; Centocor, Inc.
Recruiting - verified December 2010 - Condition: Type 1 Diabetes
Interventions: Drug: Estradiol, medroxyprogesterone, hydrocortisone, growth hormone; Drug: Matching placebo
Sponsors: Sansum Diabetes Research Institute; Sansum Diabetes Research Institute
Not yet recruiting - verified July 2011 - Condition: Acute Migraine
Interventions: Drug: Metoclorpamide; Drug: Ketorolac; Drug: Valproate
Sponsors: Montefiore Medical Center; Montefiore Medical Center
Recruiting - verified April 2012 - Condition: Rheumatoid Arthritis
Interventions: Drug: Fostamatinib and placebo injections; Drug: Fostamatinib and placebo injections; Drug: Fostamatinib and placebo injections; Drug: Adalimumab and placebo of fostamatinib; Drug: Placebo of fostamatinib, fostamatinib, and placebo injections
Sponsors: AstraZeneca; AstraZeneca
Recruiting - verified March 2012 - Condition: Ulcerative Colitis
Intervention: Drug: Oral OKT3
Sponsors: Massachusetts General Hospital; Massachusetts General Hospital; Brigham and Women's Hospital
Recruiting - verified August 2011 - Conditions: Mesolthelioma; Esophageal Cancer; Lung Cancer
Interventions: Drug: Celecoxib; Drug: ISCOMATRIX (TM) Adjuvant; Biological: Autologous Tumor Cell Vaccine
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified January 2012 - Conditions: Episodic Migraine; Chronic Migraine
Interventions: Drug: Aspirin (acetylsalicylic acid); Drug: Placebo
Sponsors: Swedish Medical Center; Swedish Medical Center; University of Washington; National Headache Foundation; Wadsworth Foundation; Accumetrics, Inc.
Recruiting - verified July 2011 - Conditions: High Risk Polycythemia Vera; High Risk Essential Thrombocythemia
Interventions: Drug: PEGASYS; Drug: Hydroxyurea; Drug: Aspirin
Sponsors: Myeloproliferative Disorders-Research Consortium; Myeloproliferative Disorders-Research Consortium; National Cancer Institute (NCI); Roche Pharma AG
Recruiting - verified December 2011 - Conditions: High Risk Polycythemia Vera; High Risk Essential Thrombocythemia
Interventions: Drug: PEGASYS; Drug: Aspirin
Sponsors: Myeloproliferative Disorders-Research Consortium; Myeloproliferative Disorders-Research Consortium; National Cancer Institute (NCI); Roche Pharma AG
Recruiting - verified February 2012 - Condition: Leukemia
Interventions: Biological: alemtuzumab; Drug: cyclophosphamide; Drug: cytarabine; Drug: dasatinib; Drug: daunorubicin hydrochloride; Drug: dexamethasone; Drug: etoposide phosphate; Drug: fludarabine phosphate; Drug: leucovorin calcium; Drug: melphalan; Drug: mercaptopurine; Drug: methotrexate; Drug: vincristine sulfate; Genetic: polymerase chain reaction; Other: laboratory biomarker analysis; Other: pharmacological study; Procedure: allogeneic hematopoietic stem cell transplantation; Procedure: autologous hematopoietic stem cell transplantation; Procedure: peripheral blood stem cell transplantation
Sponsors: National Cancer Institute (NCI); Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified April 2012 - Condition: Prostate Cancer
Interventions: Drug: Abiraterone Acetate; Drug: Prednisone; Drug: Sunitinib; Drug: Dasatinib
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Bristol-Myers Squibb; Ortho Biotech, Inc.; Pfizer
Recruiting - verified April 2012 - Condition: Multiple Myeloma, Plasma Cell Leukemia
Interventions: Drug: ARRY-520, KSP(Eg5) inhibitor; intravenous; Drug: Bortezomib, proteasome inhibitor; intravenous; Drug: Dexamethasone, steroid; oral; Drug: Filgrastim, granulocyte-colony stimulating factor (G-CSF); subcutaneous
Sponsors: Array BioPharma; Array BioPharma
Recruiting - verified June 2011 - Condition: Radiation-induced Dermatitis
Intervention: Drug: Curcumin
Sponsors: University of Rochester; University of Rochester; National Cancer Institute (NCI)
Recruiting - verified March 2012 - Conditions: Ovarian Cancer; Fallopian Tube Cancer; Peritoneal Cancer
Interventions: Drug: carboplatin; Drug: carboplatin
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center; National Institutes of Health (NIH)
Recruiting - verified November 2011 - Conditions: Stevens-Johnson Syndrome; Corneal Blindness
Intervention: Drug: Infliximab
Sponsors: Massachusetts Eye and Ear Infirmary; Massachusetts Eye and Ear Infirmary; Massachusetts Eye Research and Surgery Institution
Recruiting - verified May 2012 - Condition: Pulmonary Disease, Chronic Obstructive
Interventions: Drug: Budesonide+ ipratropium/albuterol; Drug: budesonide/formoterol plus ipratropium/albuterol; Drug: Ipratropium/albuterol
Sponsors: National Jewish Health; National Jewish Health; AstraZeneca
Recruiting - verified April 2012 - Conditions: Asthma; Reactive Airway Disease
Interventions: Drug: Dexamethasone; Drug: Prednisone
Sponsors: Alameda County Medical Center; Alameda County Medical Center
Recruiting - verified January 2012 - Condition: Cancer Patients Who Are Undergoing Chemotherapy Treatments and Are Experiencing Cognitive Difficulties.
Interventions: Drug: Ibuprofen; Behavioral: Home-Based Exercise (EXCAP); Drug: Placebo (sugar pill)
Sponsors: University of Rochester; University of Rochester; National Institutes of Health (NIH)
Recruiting - verified August 2011 - Condition: Multiple Myeloma
Interventions: Drug: Lenalidomide; Drug: Dexamethasone; Drug: Dexamethasone (Oral); Drug: Dexamethasone (IV); Biological: Elotuzumab (BMS-901608; HuLuc63)
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb; Abbott Biotherapeutics Corp.
Recruiting - verified May 2012 - Condition: Myeloma
Interventions: Drug: Palifermin; Drug: Dexamethasone; Drug: Gemcitabine; Drug: Busulfan; Drug: Melphalan; Procedure: Stem Cell Transplant
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified March 2012 - Condition: Castrate-Resistant Prostate Cancer
Interventions: Drug: ISIS EIF4E Rx; Drug: ISIS EIF4E Rx; Drug: ISIS EIF4E Rx; Drug: Prednisone; Drug: Docetaxel
Sponsors: Isis Pharmaceuticals; Isis Pharmaceuticals
Recruiting - verified April 2012 - Condition: Episodic Migraine
Interventions: Other: saline placebo; Drug: Ibuprofen
Sponsors: Thomas Jefferson University; Thomas Jefferson University
Recruiting - verified June 2011 - Conditions: Choroidal Neovascularization; Myopia; Punctate Inner Choroidopathy (PIC); Multifocal Choroiditis; Ocular Histoplasmosis Syndrome; Central Serous Chorioretinopathy (CSC); Angioid Streaks; Trauma, or Hereditary Eye Diseases
Interventions: Drug: Bevacizumab (Avastin; Genentech, Inc.); Drug: Bevacizumab, Dexamethasone, Verteporfin Photodynamic Therapy
Sponsors: Massachusetts Eye and Ear Infirmary; Massachusetts Eye and Ear Infirmary
Recruiting - verified April 2012 - Conditions: Macular Edema; Central Retinal Vein Occlusion
Interventions: Drug: Ozurdex; Drug: Avastin
Sponsors: Long Island Vitreoretinal Consultants; Long Island Vitreoretinal Consultants
Recruiting - verified April 2012 - Conditions: Migraine Disorders; Migraine Headache; Migraine; Acute Migraine
Interventions: Drug: Topical, intra-oral ketoprofen gel; Other: Placebo gel
Sponsors: Behar, Caren, M.D.; Behar, Caren, M.D.
Not yet recruiting - verified October 2010 - Condition: Osteoarthritis (OA) of the Knee
Interventions: Drug: Triamcinolone Acetonide; Drug: 0.9% Sodium Chloride Injection as Placebo
Sponsors: Tufts Medical Center; Tufts Medical Center
Recruiting - verified March 2012 - Condition: Asthma
Interventions: Drug: budesonide/formoterol or fluticasone/salmeterol; Drug: budesonide/formoterol or fluticasone/salmeterol
Sponsors: Gelb, Arthur F., M.D.; Gelb, Arthur F., M.D.
Recruiting - verified August 2011 - Condition: Relapsed AL Amyloidosis
Interventions: Drug: Bendamustine; Drug: Dexamethasone
Sponsors: University of Pittsburgh; University of Pittsburgh; Cephalon
Not yet recruiting - verified June 2011 - Condition: Nasal Polyps
Interventions: Drug: Triamcinolone; Drug: Triamcinolone
Sponsors: Steward St. Elizabeth's Medical Center of Boston, Inc.; Steward St. Elizabeth's Medical Center of Boston, Inc.
Recruiting - verified July 2011 - Condition: Head And Neck Cancer
Interventions: Other: Placebo; Drug: Curcumin; Drug: Armodafinil; Drug: Minocycline; Drug: Bupropion
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; National Cancer Institute (NCI)
Not yet recruiting - verified November 2011 - Condition: Psoriatic Arthritis
Interventions: Drug: Apremilast; Drug: • Placebo
Sponsors: Celgene Corporation; Celgene Corporation
Recruiting - verified June 2011 - Condition: Esophageal Cancer
Interventions: Drug: Docetaxel; Drug: 5-FU; Radiation: Radiotherapy; Procedure: Esophagectomy; Drug: Dexamethasone
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified May 2012 - Condition: Multiple Myeloma
Interventions: Drug: VELCADE; Drug: Lenalidomide; Drug: Dexamethasone; Drug: DVT prophylaxis; Drug: Bisphosphonates; Drug: Liposomal doxorubicin; Drug: Dexamethasone
Sponsors: Vanderbilt-Ingram Cancer Center; Vanderbilt-Ingram Cancer Center
Recruiting - verified July 2011 - Condition: Refractory Multiple Myeloma
Interventions: Drug: pomalidomide; Drug: bortezomib; Drug: dexamethasone; Other: laboratory biomarker analysis; Other: gene expression analysis
Sponsors: Mayo Clinic; Mayo Clinic; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Condition: Spondylitis, Ankylosing
Interventions: Drug: Part I - etoricoxib 60 mg; Drug: Part I - etoricoxib 90 mg; Drug: Part I- naproxen 1000 mg; Drug: Part I - Placebo to etoricoxib 60 mg; Drug: Part I - Placebo to etoricoxib 90 mg; Drug: Part I - Placebo to naproxen 500 mg; Drug: Part II- etoricoxib 60 mg; Drug: Part II- etoricoxib 90 mg; Drug: Part II- naproxen 1000 mg; Drug: Part II - Placebo to etoricoxib 60 mg; Drug: Part II - Placebo to etoricoxib 90 mg; Drug: Part II - Placebo to naproxen 500 mg
Sponsors: Merck; Merck
Recruiting - verified May 2012 - Condition: Arthritis, Rheumatoid
Interventions: Drug: Part 1: Etoricoxib 60 mg; Drug: Part 1: Etoricoxib 90 mg; Drug: Part 2: Etoricoxib 60 mg; Drug: Part 2: Etoricoxib 90 mg; Drug: Part 1: Placebo to Etoricoxib 60 mg; Drug: Part 1: Placebo to Etoricoxib 90 mg; Drug: Part 2: Placebo to Etoricoxib 60 mg; Drug: Part 2: Placebo to Etoricoxib 90 mg
Sponsors: Merck; Merck
Recruiting - verified May 2012 - Condition: Multiple Myeloma
Interventions: Drug: Lenalidomide; Drug: Bortezomib; Drug: Dexamethasone; Procedure: Autologous Stem Cell Transplant
Sponsors: Dana-Farber Cancer Institute; Dana-Farber Cancer Institute; Celgene Corporation; Millennium Pharmaceuticals, Inc.; Massachusetts General Hospital; Beth Israel Deaconess Medical Center; Emory University; University of Michigan; Fox Chase Cancer Center; Memorial Sloan-Kettering Cancer Center; Fred Hutchinson Cancer Research Center; Barbara Ann Karmanos Cancer Institute; Duke University; University of California, San Francisco; University of Chicago; M.D. Anderson Cancer Center; UNC Lineberger Comprehensive Cancer Center
Recruiting - verified July 2011 - Condition: Atrial Fibrillation
Interventions: Drug: Ablation plus prednisone; Drug: Ablation plus placebo
Sponsors: University of Kansas; University of Kansas
Recruiting - verified June 2011 - Conditions: Diarrhea; Gastrointestinal Complications; Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: sulfasalazine; Other: placebo
Sponsors: National Cancer Institute (NCI); North Central Cancer Treatment Group; National Cancer Institute (NCI)
Recruiting - verified April 2012 - Condition: Spinal Cord Injury
Intervention: Drug: Salsalate
Sponsors: University of Miami; University of Miami
Recruiting - verified November 2011 - Condition: Acute Gout
Intervention: Drug: ACZ885
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified April 2012 - Conditions: Pseudophakia; Cataract Surgery
Interventions: Drug: Pred Forte; Drug: Lotemax
Sponsors: Innovative Medical; Innovative Medical
Recruiting - verified October 2011 - Conditions: Lymphoma; Nonneoplastic Condition
Interventions: Biological: rituximab; Drug: EPOCH regimen; Drug: cyclophosphamide; Drug: doxorubicin hydrochloride; Drug: etoposide; Drug: prednisone; Drug: vincristine sulfate; Drug: vorinostat; Other: R-CHOP regimen
Sponsors: National Cancer Institute (NCI); AIDS Associated Malignancies Clinical Trials Consortium; National Cancer Institute (NCI)
Recruiting - verified August 2011 - Condition: Prostate Cancer
Interventions: Drug: Orteronel + prednisone; Drug: Placebo + prednisone
Sponsors: Millennium Pharmaceuticals, Inc.; Millennium Pharmaceuticals, Inc.
Recruiting - verified February 2012 - Condition: Prostate Cancer
Interventions: Drug: Orteronel + prednisone; Drug: Placebo + prednisone
Sponsors: Millennium Pharmaceuticals, Inc.; Millennium Pharmaceuticals, Inc.
Recruiting - verified February 2012 - Condition: Multiple Sclerosis, Primary Progressive
Interventions: Drug: ocrelizumab; Drug: Placebo; Drug: methylprednisolone
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified April 2012 - Condition: Leukemia
Interventions: Drug: cyclophosphamide; Drug: cytarabine; Drug: dexamethasone; Drug: doxorubicin hydrochloride; Drug: leucovorin calcium; Drug: mercaptopurine; Drug: methotrexate; Drug: pegaspargase; Drug: thioguanine; Drug: vincristine sulfate
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Condition: Prostate Cancer
Interventions: Drug: Custirsen Sodium, Docetaxel, Prednisone; Drug: Docetaxel, Prednisone
Sponsors: Teva Pharmaceutical Industries; Teva Pharmaceutical Industries; OncoGenex Technologies
Recruiting - verified May 2012 - Condition: Depression
Interventions: Drug: Placebo infusion; Drug: ibuprofen intravenous
Sponsors: University of Medicine and Dentistry New Jersey; University of Medicine and Dentistry New Jersey
Recruiting - verified December 2011 - Condition: Hearing Loss, Sensorineural
Intervention: Drug: Fludrocortisone
Sponsors: Oregon Health and Science University; Oregon Health and Science University
Recruiting - verified August 2011 - Condition: Early Rheumatoid Arthritis
Interventions: Biological: adalimumab; Drug: methotrexate
Sponsors: Abbott; Abbott
Recruiting - verified February 2012 - Condition: Rheumatoid Arthritis
Interventions: Biological: Humira (adalimumab); Drug: Methotrexate (MTX)
Sponsors: Abbott; Abbott
Recruiting - verified December 2011 - Condition: Crohn's Disease
Interventions: Biological: Infliximab; Drug: Placebo
Sponsors: Janssen Biotech, Inc.; Janssen Biotech, Inc.
Recruiting - verified May 2012 - Conditions: Relapsed Lymphoma; B Cell Non-Hodgkin Lymphoma; Refractory Lymphoma; High Risk Chronic Lymphocytic Leukemia
Interventions: Drug: Rituximab; Biological: Interleukin-2; Biological: Natural killer cells; Drug: Cyclophosphamide; Drug: Methylprednisolone; Drug: Fludarabine
Sponsors: Masonic Cancer Center, University of Minnesota; Masonic Cancer Center, University of Minnesota
Recruiting - verified April 2012 - Condition: Lung Inflammation
Interventions: Drug: Rosiglitazone; Drug: Zileuton; Drug: Rosiglitazone placebo; Drug: Zileuton placebo
Sponsors: Washington University School of Medicine; Washington University School of Medicine; Doris Duke Charitable Foundation
Recruiting - verified July 2011 - Condition: Adenomatous Polyposis Coli
Interventions: Drug: Erlotinib; Drug: Sulindac; Drug: Placebo A; Drug: Placebo B
Sponsors: University of Utah; University of Utah; National Cancer Institute (NCI)
Recruiting - verified September 2011 - Condition: Solid Tumor
Intervention: Drug: PEGPH20
Sponsors: Halozyme Therapeutics; Halozyme Therapeutics
Recruiting - verified June 2011 - Conditions: Keratoconus; Ectasia; Degeneration
Interventions: Drug: Ciprofloxicine or Vigamox or other.; Drug: Nonsteroidal (Acular, Acuvail, Voltaren Xibrom, etc); Drug: Steroid (FML, Pred Forte, Flarex, etc.)
Sponsors: Innovative Medical; Innovative Medical
Recruiting - verified April 2012 - Condition: Menorrhagia
Interventions: Drug: Estradiol 30 mcg / Levonorgestrel 150 mcg monophasic oral contraceptive pills; Drug: Naproxen sodium pills; Device: Nova Sure Radiofrequency Endometrial Ablation
Sponsors: Mayo Clinic; Mayo Clinic; Hologic, Inc.
Recruiting - verified January 2012 - Condition: Necrotizing Enterocolitis
Interventions: Drug: hydrocortisone; Drug: placebo
Sponsors: NorthShore University HealthSystem Research Institute; NorthShore University HealthSystem Research Institute; University of Chicago
Recruiting - verified March 2009 - Condition: Head and Neck Cancer
Intervention: Dietary Supplement: Microgranular Curcumin C3 Complex®
Sponsors: Louisiana State University Health Sciences Center Shreveport; Louisiana State University Health Sciences Center Shreveport; Feist-Weiller Cancer Center at Louisiana State University Health Sciences; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Condition: Coronary Graft Patency
Interventions: Drug: clopidogrel; Drug: sugar pill
Sponsors: Brooke Army Medical Center; Ahmad Slim; Bristol-Myers Squibb
Recruiting - verified February 2012 - Condition: Refractory Multiple Myeloma
Interventions: Drug: azacitidine; Drug: lenalidomide; Drug: dexamethasone; Other: DNA methylation analysis; Other: gene expression analysis; Other: bone marrow aspiration; Other: immunohistochemistry staining method; Other: reverse transcriptase-polymerase chain reaction; Other: flow cytometry
Sponsors: Case Comprehensive Cancer Center; Case Comprehensive Cancer Center; National Cancer Institute (NCI)
Recruiting - verified February 2012 - Condition: PCOS
Interventions: Drug: Dexamethasone and recombinant hCG; Drug: dexamethasone, human chorionic gonadotrpoin (hCG)
Sponsors: University of California, San Diego; University of California, San Diego; University of Virginia
Recruiting - verified August 2011 - Condition: Colorectal Cancer
Interventions: Drug: celecoxib; Drug: fluorouracil; Drug: leucovorin calcium; Drug: oxaliplatin; Other: placebo
Sponsors: National Cancer Institute (NCI); Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified February 2012 - Condition: Prostate Cancer
Interventions: Biological: fowlpox-PSA-TRICOM vaccine; Biological: vaccinia-PSA-TRICOM vaccine; Drug: docetaxel; Drug: prednisone
Sponsors: National Cancer Institute (NCI); Eastern Cooperative Oncology Group; National Cancer Institute (NCI)
Recruiting - verified September 2011 - Condition: Cervical Radiculopathy
Interventions: Other: Gabapentin and/or Nortriptyline, Physical therapy; Procedure: Epidural Steroid Injections (ESI); Other: Combination treatment
Sponsors: Johns Hopkins University; Johns Hopkins University; Walter Reed Army Medical Center
Recruiting - verified September 2010 - Conditions: Lung Cancer; Esophageal Cancer; Malignant Pleural Mesothelioma; Thymoma; Thymic Carcinoma
Interventions: Biological: Allogeneic Tumor Cell Vaccine (K562); Drug: Celecoxib; Drug: cyclophosphamide
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified March 2012 - Condition: Migraine
Interventions: Drug: sumatriptan/naproxen sodium; Drug: Placebo
Sponsors: Johns Hopkins University; Johns Hopkins University; University of Michigan; University of Toledo Health Science Campus; Dartmouth-Hitchcock Medical Center
Recruiting - verified August 2011 - Condition: Pelvic Inflammatory Disease
Interventions: Drug: ceftriaxone, doxycycline, and placebo; Drug: ceftriaxone, doxycycline, metronidazole
Sponsors: University of Pittsburgh; Harold Wiesenfeld; National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified February 2012 - Condition: Asthma
Interventions: Drug: budesonide; Drug: placebo
Sponsors: AstraZeneca; AstraZeneca
Recruiting - verified May 2012 - Condition: Lymphoma
Interventions: Biological: bleomycin sulfate; Drug: ABVD regimen; Drug: BEACOPP regimen; Drug: cyclophosphamide; Drug: dacarbazine; Drug: doxorubicin hydrochloride; Drug: etoposide; Drug: prednisone; Drug: procarbazine hydrochloride; Drug: vinblastine sulfate; Drug: vincristine sulfate; Other: laboratory biomarker analysis; Procedure: computed tomography; Radiation: fludeoxyglucose F 18; Radiation: radiation therapy
Sponsors: National Cancer Institute (NCI); Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Condition: Chronic Myelogenous Leukemia
Intervention: Drug: Zileuton
Sponsors: University of Massachusetts, Worcester; University of Massachusetts, Worcester
Recruiting - verified February 2012 - Conditions: Myelodysplastic Syndrome; MDS
Interventions: Drug: Prednisone; Drug: Lenalidomide
Sponsors: H. Lee Moffitt Cancer Center and Research Institute; H. Lee Moffitt Cancer Center and Research Institute; Celgene Corporation
Recruiting - verified February 2012 - Condition: Ulcerative Colitis
Interventions: Drug: MMX Mesalamine; Drug: MMX Mesalamine; Drug: MMX Mesalamine
Sponsors: Shire Development LLC; Shire Development LLC
Recruiting - verified April 2012 - Condition: Sickle Cell Disease
Intervention: Drug: Zileuton
Sponsors: Children's Hospital Medical Center, Cincinnati; Children's Hospital Medical Center, Cincinnati
Recruiting - verified January 2012 - Condition: Uveitis
Interventions: Drug: adalimumab; Drug: prednisone; Drug: prednisone; Drug: adalimumab placebo
Sponsors: Abbott; Abbott
Recruiting - verified February 2012 - Condition: Uveitis
Interventions: Drug: adalimumab; Drug: prednisone; Drug: adalimumab placebo; Drug: prednisone
Sponsors: Abbott; Abbott
Recruiting - verified February 2012 - Condition: Inflammation Following Cataract Surgery
Interventions: Drug: Difluprednate 0.05% ophthalmic emulsion; Drug: Prednisolone acetate 1.0% ophthalmic suspension
Sponsors: Alcon Research; Alcon Research
Recruiting - verified November 2011 - Condition: Castration Resistant Prostate Cancer
Interventions: Drug: OGX-427 and Prednisone; Drug: Prednisone
Sponsors: British Columbia Cancer Agency; British Columbia Cancer Agency; OncoGenex Technologies, Inc.
Recruiting - verified December 2011 - Condition: Lymphoma
Interventions: Biological: bleomycin sulfate; Drug: ABVD regimen; Drug: BEACOPP regimen; Drug: cyclophosphamide; Drug: dacarbazine; Drug: doxorubicin hydrochloride; Drug: etoposide; Drug: prednisone; Drug: procarbazine hydrochloride; Drug: vinblastine sulfate; Drug: vincristine sulfate; Other: laboratory biomarker analysis; Procedure: computed tomography; Radiation: fludeoxyglucose F 18; Radiation: radiation therapy
Sponsors: National Cancer Institute (NCI); Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified April 2012 - Condition: Asthma
Interventions: Drug: fluticasone propionate and salmeterol; Drug: budesonide and formoterol
Sponsors: National Jewish Health; National Jewish Health
Recruiting - verified July 2011 - Conditions: Asthma; Rhinitis; Sinusitis
Interventions: Drug: Mometasone Furoate monohydrate; Other: Placebo
Sponsors: American Lung Association Asthma Clinical Research Centers; American Lung Association Asthma Clinical Research Centers; National Institutes of Health (NIH); National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified June 2011 - Condition: Multiple Myeloma
Interventions: Drug: Lenalidomide; Drug: lenalidomide, bortezomib and dexamethasone; Drug: Lenalidomide
Sponsors: National Heart, Lung, and Blood Institute (NHLBI); National Heart, Lung, and Blood Institute (NHLBI); Blood and Marrow Transplant Clinical Trials Network; National Cancer Institute (NCI)
Recruiting - verified March 2012 - Conditions: Adult Nasal Type Extranodal NK/T-cell Lymphoma; Anaplastic Large Cell Lymphoma; Angioimmunoblastic T-cell Lymphoma; Cutaneous B-cell Non-Hodgkin Lymphoma; Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue; Intraocular Lymphoma; Nodal Marginal Zone B-cell Lymphoma; Peripheral T-cell Lymphoma; Recurrent Adult Burkitt Lymphoma; Recurrent Adult Diffuse Large Cell Lymphoma; Recurrent Adult Diffuse Mixed Cell Lymphoma; Recurrent Adult Diffuse Small Cleaved Cell Lymphoma; Recurrent Adult Grade III Lymphomatoid Granulomatosis; Recurrent Adult Hodgkin Lymphoma; Recurrent Adult Immunoblastic Large Cell Lymphoma; Recurrent Adult Lymphoblastic Lymphoma; Recurrent Adult T-cell Leukemia/Lymphoma; Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma; Recurrent Grade 1 Follicular Lymphoma; Recurrent Grade 2 Follicular Lymphoma; Recurrent Grade 3 Follicular Lymphoma; Recurrent Mantle Cell Lymphoma; Recurrent Marginal Zone Lymphoma; Recurrent Mycosis Fungoides/Sezary Syndrome; Recurrent Small Lymphocytic Lymphoma; Refractory Multiple Myeloma; Small Intestine Lymphoma; Splenic Marginal Zone Lymphoma; Waldenström Macroglobulinemia
Interventions: Drug: bendamustine hydrochloride; Drug: dexamethasone; Biological: filgrastim; Procedure: leukapheresis; Other: laboratory biomarker analysis; Other: flow cytometry; Drug: etoposide
Sponsors: Fred Hutchinson Cancer Research Center; Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Condition: Chronic GVHD
Interventions: Drug: Sirolimus + calcineurin inhibitor + prednisone; Drug: Sirolimus + prednisone
Sponsors: National Heart, Lung, and Blood Institute (NHLBI); National Heart, Lung, and Blood Institute (NHLBI); National Cancer Institute (NCI); Blood and Marrow Transplant Clinical Trials Network
Recruiting - verified April 2012 - Conditions: Ovarian Cancer; Fallopian Tube Cancer; Primary Peritoneal Cancer; Breast Cancer
Interventions: Drug: Fludarabine; Drug: Cyclophosphamide; Drug: Cyclosporine; Biological: Natural killer cells; Drug: IL-2; Drug: Methylprednisolone; Drug: Methylprednisolone; Drug: Interleukin-2
Sponsors: Masonic Cancer Center, University of Minnesota; Masonic Cancer Center, University of Minnesota
Recruiting - verified March 2012 - Condition: Hemophagocytic Lymphohistiocytosis
Interventions: Drug: ATG, rabbit; Drug: Etoposide; Drug: Intrathecal Methotrexate; Drug: hydrocortisone
Sponsors: Children's Hospital Medical Center, Cincinnati; Children's Hospital Medical Center, Cincinnati
Recruiting - verified January 2012 - Conditions: Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome; Adult Acute Lymphoblastic Leukemia in Remission; Adult Acute Megakaryoblastic Leukemia (M7); Adult Acute Minimally Differentiated Myeloid Leukemia (M0); Adult Acute Monoblastic Leukemia (M5a); Adult Acute Monocytic Leukemia (M5b); Adult Acute Myeloid Leukemia in Remission; Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities; Adult Acute Myeloid Leukemia With t(16;16)(p13;q22); Adult Erythroleukemia (M6a); Adult Nasal Type Extranodal NK/T-cell Lymphoma; Adult Pure Erythroid Leukemia (M6b); B-cell Adult Acute Lymphoblastic Leukemia; B-cell Childhood Acute Lymphoblastic Leukemia; Blastic Phase Chronic Myelogenous Leukemia; Burkitt Lymphoma; Childhood Acute Erythroleukemia (M6); Childhood Acute Lymphoblastic Leukemia in Remission; Childhood Acute Megakaryocytic Leukemia (M7); Childhood Acute Minimally Differentiated Myeloid Leukemia (M0); Childhood Acute Monoblastic Leukemia (M5a); Childhood Acute Monocytic Leukemia (M5b); Childhood Acute Myeloid Leukemia in Remission; Childhood Chronic Myelogenous Leukemia; Childhood Diffuse Large Cell Lymphoma; Childhood Immunoblastic Large Cell Lymphoma; Childhood Myelodysplastic Syndromes; Childhood Nasal Type Extranodal NK/T-cell Lymphoma; Chronic Myelomonocytic Leukemia; Chronic Phase Chronic Myelogenous Leukemia; Cutaneous B-cell Non-Hodgkin Lymphoma; de Novo Myelodysplastic Syndromes; Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue; Juvenile Myelomonocytic Leukemia; Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable; Nodal Marginal Zone B-cell Lymphoma; Previously Treated Myelodysplastic Syndromes; Prolymphocytic Leukemia; Recurrent Adult Acute Lymphoblastic Leukemia; Recurrent Adult Acute Myeloid Leukemia; Recurrent Adult Burkitt Lymphoma; Recurrent Adult Diffuse Large Cell Lymphoma; Recurrent Adult Diffuse Mixed Cell Lymphoma; Recurrent Adult Diffuse Small Cleaved Cell Lymphoma; Recurrent Adult Grade III Lymphomatoid Granulomatosis; Recurrent Adult Immunoblastic Large Cell Lymphoma; Recurrent Adult Lymphoblastic Lymphoma; Recurrent Childhood Acute Lymphoblastic Leukemia; Recurrent Childhood Acute Myeloid Leukemia; Recurrent Childhood Anaplastic Large Cell Lymphoma; Recurrent Childhood Grade III Lymphomatoid Granulomatosis; Recurrent Childhood Large Cell Lymphoma; Recurrent Childhood Lymphoblastic Lymphoma; Recurrent Childhood Small Noncleaved Cell Lymphoma; Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma; Recurrent Grade 1 Follicular Lymphoma; Recurrent Grade 2 Follicular Lymphoma; Recurrent Grade 3 Follicular Lymphoma; Recurrent Mantle Cell Lymphoma; Recurrent Marginal Zone Lymphoma; Recurrent Mycosis Fungoides/Sezary Syndrome; Recurrent Small Lymphocytic Lymphoma; Refractory Chronic Lymphocytic Leukemia; Relapsing Chronic Myelogenous Leukemia; Secondary Acute Myeloid Leukemia; Secondary Myelodysplastic Syndromes; Secondary Myelofibrosis; Splenic Marginal Zone Lymphoma; Stage I Chronic Lymphocytic Leukemia; Stage II Chronic Lymphocytic Leukemia; Stage III Chronic Lymphocytic Leukemia; Stage IV Chronic Lymphocytic Leukemia; T-cell Adult Acute Lymphoblastic Leukemia; T-cell Childhood Acute Lymphoblastic Leukemia; T-cell Large Granular Lymphocyte Leukemia; Waldenstrom Macroglobulinemia
Interventions: Procedure: double-unit umbilical cord blood transplantation; Other: cytogenetic analysis; Procedure: bone marrow aspiration; Other: fluorescence in situ hybridization; Drug: busulfan; Drug: cyclophosphamide; Drug: anti-thymocyte globulin; Drug: methylprednisolone; Drug: cyclosporine; Drug: mycophenolate mofetil; Other: flow cytometry; Procedure: allogeneic hematopoietic stem cell transplantation
Sponsors: Case Comprehensive Cancer Center; Case Comprehensive Cancer Center
Recruiting - verified January 2012 - Conditions: Burkitt Lymphoma; Diffuse Large B-cell Lymphoma, c-MYC Positive
Interventions: Drug: rituximab; Drug: etoposide; Drug: cyclophosphamide; Drug: doxorubicin; Drug: vincristine; Drug: prednisone; Drug: filgrastim
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified September 2011 - Condition: Posttraumatic Stress Disorder
Interventions: Drug: Dexamethasone; Drug: Placebo (sugar pill)
Sponsors: Department of Veterans Affairs; Department of Veterans Affairs
Recruiting - verified January 2012 - Condition: Chronic Beryllium Disease
Interventions: Drug: Mesalamine; Drug: Placebo
Sponsors: National Jewish Health; National Jewish Health
Recruiting - verified December 2011 - Condition: Obstructive Sleep Apnea
Interventions: Drug: budesonide nasal spray and a montelukast pill; Drug: Placebo: sugar pill and salt water nasal spray
Sponsors: Romaker & Associates; Romaker & Associates; Merck; AstraZeneca
Recruiting - verified July 2011 - Condition: Prostate Cancer
Interventions: Drug: Abiraterone Acetate; Drug: Prednisone; Drug: LHRHa
Sponsors: Cougar Biotechnology, Inc.; Cougar Biotechnology, Inc.
Recruiting - verified December 2010 - Condition: PTSD
Interventions: Behavioral: Prolonged Exposure therapy; Drug: Hydrocortisone; Behavioral: Prolonged Exposure therapy
Sponsors: Bronx VA Medical Center; Bronx VA Medical Center; Lightfighter Trust
Recruiting - verified February 2012 - Conditions: Crohn's Disease; Rheumatoid Arthritis
Intervention:
Sponsors: University of California, San Diego; University of California, San Diego; The Organization of Teratology Information Specialists; Abbott
Recruiting - verified April 2012 - Condition: Cardiovascular Disease
Interventions: Drug: Active Clonidine; Drug: Placebo Clonidine; Drug: Active ASA; Drug: Placebo ASA
Sponsors: McMaster University; Hamilton Health Sciences Corporation; McMaster University
Recruiting - verified December 2011 - Condition: Scalp Psoriasis
Intervention: Drug: LEO 80185 (Taclonex® Scalp topical suspension/Xamiol® gel)
Sponsors: LEO Pharma; LEO Pharma
Recruiting - verified March 2011 - Condition: Waldenstrom's Macroglobulinemia
Interventions: Drug: pomalidomide; Drug: dexamethasone; Drug: rituximab
Sponsors: Dana-Farber Cancer Institute; Dana-Farber Cancer Institute; Celgene Corporation
Recruiting - verified June 2011 - Trial on the Effect of Budesonide/Formoterol and Inhaled Budesonide Alone on Exercise-Induced AsthmaCondition: Exercise Induced Asthma
Interventions: Drug: Budesonide/Formoterol; Drug: Budesonide
Sponsors: Children's Hospital Boston; Children's Hospital Boston; Brigham and Women's Hospital
Recruiting - verified June 2011 - Condition: CNI Side Effects
Interventions: Drug: Cyclosporine & Cellcept; Drug: Prograf & Cellcept; Drug: Cyclosporine, Cellcept, & Prednisone; Drug: Prograf, Cellcept, & Prednisone; Drug: Low Dose CNI (Cyclosporine or FK) and Cellcept; Drug: Rapamune and Cellcept; Drug: Low dose CNI (CSA or FK), Rapamune, & Prednisone; Drug: Rapamune, Cellcept, & Prednisone
Sponsors: University of Minnesota - Clinical and Translational Science Institute; University of Minnesota - Clinical and Translational Science Institute; Roche Pharma AG; Wyeth is now a wholly owned subsidiary of Pfizer; Genzyme
Recruiting - verified April 2012 - Condition: Migraine Disorders
Interventions: Drug: Sumatriptan; Drug: Naratriptan; Drug: Sumatriptan-naproxen combination
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified February 2012 - Conditions: Inflammation; Uveitis
Interventions: Procedure: Fluocinolone Acetonide 0.59 mg; Procedure: Fluocinolone Acetonide 2.1 mg
Sponsors: Bausch & Lomb, Inc.; Bausch & Lomb, Inc.
Recruiting - verified March 2012 - Condition: Non-infectious, Non-necrotizing Anterior Scleritis
Interventions: Drug: Dexamethasone Phosphate Ophthalmic Solution (EGP-437); Drug: Dexamethasone phosphate ophthalmic solution
Sponsors: University of Pennsylvania; John Kempen; FDA Office of Orphan Products Development; Eyegate Pharmaceuticals, Inc.
Recruiting - verified May 2012 - Conditions: Multiple Myeloma; Stage I Multiple Myeloma; Stage II Multiple Myeloma; Stage III Multiple Myeloma
Interventions: Drug: carfilzomib; Drug: cyclophosphamide; Drug: thalidomide; Drug: dexamethasone
Sponsors: Mayo Clinic; Mayo Clinic
Recruiting - verified April 2012 - Condition: Post-Traumatic Headache
Interventions: Drug: sumatriptan/naproxen sodium; Drug: Placebo
Sponsors: Cady, Roger, M.D.; Cady, Roger, M.D.; GlaxoSmithKline
Recruiting - verified April 2012 - Condition: Lymphoma, B-Cell
Interventions: Drug: inotuzumab ozogamicin+rituximab +cyclophosphamide+vincristine+prednisone; Drug: inotuzumab ozogamicin+rituximab+gemcitabine+cisplatinum+dexamethasone
Sponsors: Pfizer; Pfizer; UCB, Inc.
Recruiting - verified May 2012 - Condition: Multiple Myeloma
Interventions: Drug: Lenalidomide; Drug: Prednisone; Drug: Dexamethasone
Sponsors: H. Lee Moffitt Cancer Center and Research Institute; H. Lee Moffitt Cancer Center and Research Institute; Celgene Corporation
Recruiting - verified February 2012 - Condition: Anemia, Sickle Cell
Intervention: Drug: alpha-lipoic acid and acetyl-L-carnitine
Sponsors: Children's Hospital & Research Center Oakland; Children's Hospital & Research Center Oakland; National Center for Complementary and Alternative Medicine (NCCAM)
Recruiting - verified August 2011 - Condition: Advanced Cancer
Interventions: Drug: Docetaxel (Taxotere); Drug: Sirolimus (Rapamycin); Drug: Prednisone
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified May 2012 - Condition: Prostate Cancer
Interventions: Drug: carboplatin; Drug: everolimus; Drug: prednisone; Other: laboratory biomarker analysis; Other: pharmacological study
Sponsors: Barbara Ann Karmanos Cancer Institute; Barbara Ann Karmanos Cancer Institute; National Cancer Institute (NCI)
Recruiting - verified November 2011 - Condition: Refractory Multiple Myeloma
Interventions: Drug: bendamustine hydrochloride; Drug: lenalidomide; Drug: dexamethasone
Sponsors: Mayo Clinic; Mayo Clinic
Recruiting - verified April 2012 - Condition: Healthy
Interventions: Procedure: Aspirin ingestion followed by doing a Bleeding Volume Test; Procedure: Gatorade Placebo followed by Bleeding Volume Test.
Sponsors: Klein, Jeffrey A., M.D.; Klein, Jeffrey A., M.D.
Recruiting - verified June 2011 - Condition: Multiple Sclerosis
Interventions: Drug: ACTH; Drug: Methylprednisolone
Sponsors: University of Southern California; University of Southern California; Questcor Pharmaceuticals, Inc.
Recruiting - verified July 2011 - Condition: Lung Cancer
Interventions: Drug: carboplatin; Drug: celecoxib; Drug: gemcitabine hydrochloride; Drug: pemetrexed disodium; Other: placebo
Sponsors: National Cancer Institute (NCI); Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified February 2012 - Condition: Diverticulitis
Interventions: Drug: Mesalazine; Drug: Mesalazine; Drug: Placebo
Sponsors: Dr. Falk Pharma GmbH; Dr. Falk Pharma GmbH
Recruiting - verified January 2012 - Conditions: Functional Disability; Dementia; Heart Disease; Stroke; Cancer; Bleeding
Interventions: Drug: 100 mg enteric-coated aspirin; Drug: Placebo
Sponsors: Minneapolis Medical Research Foundation; Minneapolis Medical Research Foundation; National Health and Medical Research Council, Australia; Bayer; Monash University; Berman Center for Outcomes and Clinical Research
Recruiting - verified July 2011 - Condition: Prostate Cancer
Interventions: Drug: Ketoconazole, hydrocortisone; Drug: Ketoconazole, dexamethasone
Sponsors: University of California, San Francisco; University of California, San Francisco
Recruiting - verified March 2012 - Conditions: C-reactive Protein; Inflammation; Obesity; Oxidative Stress
Intervention: Dietary Supplement: Vitamin C (ascorbic acid)
Sponsors: University of California, Berkeley; University of California, Berkeley; Kaiser Permanente
Recruiting - verified June 2011 - Conditions: Hodgkin Lymphoma; Diffuse Large B-Cell Lymphoma
Interventions: Drug: Cylcophosphamide; Drug: Etoposide; Drug: Alemtuzumab; Drug: Doxorubicin; Drug: Prednisone; Drug: Filgrastim; Drug: Rituximab; Drug: Vincristine
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified May 2012 - Conditions: Acute Otitis Media With Tympanostomy Tubes.; Healthy Subjects With Tympanostomy Tubes.
Intervention: Drug: Ciprodex (0.3% ciprofloxacin/0.1% dexamethasone)
Sponsors: Alcon Research; Alcon Research
Recruiting - verified May 2012 - Conditions: Carcinoma, Intraductal, Noninfiltrating; DCIS; Ductal Carcinoma In Situ
Interventions: Drug: Chloroquine Standard Dose (500mg/week); Drug: Chloroquine Low Dose (250mg/week); Procedure: Breast Biopsy
Sponsors: Inova Health Care Services; Inova Health Care Services; George Mason University; Department of Defense; U.S. Army Medical Research and Materiel Command
Recruiting - verified March 2012 - Conditions: Adenocarcinoma of the Prostate; Stage II Prostate Cancer; Stage III Prostate Cancer; Stage IV Prostate Cancer
Interventions: Drug: abiraterone acetate; Drug: prednisone; Drug: leuprolide acetate; Other: mass spectrometry; Other: laboratory biomarker analysis; Other: immunohistochemistry staining method; Genetic: microarray analysis; Genetic: reverse transcriptase-polymerase chain reaction; Radiation: external beam radiation therapy; Drug: goserelin acetate
Sponsors: Fred Hutchinson Cancer Research Center; Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium; National Cancer Institute (NCI)
Recruiting - verified March 2012 - Panobinostat or Placebo With Bortezomib and Dexamethasone in Patients With Relapsed Multiple MyelomaCondition: Multiple Myeloma
Interventions: Drug: Panobinostat; Drug: Bortezomib
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified April 2012 - Condition: Eosinophilic Esophagitis
Interventions: Drug: Beclomethasone dipropionate; Drug: placebo
Sponsors: Penn State University; Penn State University
Recruiting - verified July 2011 - Conditions: Erythematotelangiectatic Rosacea; Papulopustular Rosacea
Intervention: Drug: Apremilast
Sponsors: Columbia University; Columbia University; Celgene Corporation
Recruiting - verified February 2012 - Condition: Headache
Interventions: Drug: Metoclopramide; Drug: Ketorolac
Sponsors: Montefiore Medical Center; Montefiore Medical Center
Recruiting - verified April 2012 - Conditions: Proctitis; Proctosigmoiditis
Interventions: Drug: Budesonide; Drug: Placebo
Sponsors: Salix Pharmaceuticals; Salix Pharmaceuticals
Recruiting - verified July 2011 - Conditions: Proctitis; Proctosigmoiditis
Interventions: Drug: Budesonide; Drug: Placebo
Sponsors: Salix Pharmaceuticals; Salix Pharmaceuticals
Recruiting - verified July 2011 - Condition: Chronic Stable Plaque Psoriasis
Interventions: Drug: Clobex Spray; Drug: Vectical Ointment; Procedure: Excimer Laser
Sponsors: University of California, San Francisco; University of California, San Francisco
Recruiting - verified January 2012 - Condition: Amyloidosis
Intervention: Drug: Bortezomib (Velcade) and Dexamethasone
Sponsors: Boston Medical Center; Boston Medical Center; Millennium Pharmaceuticals, Inc.
Recruiting - verified June 2011 - Conditions: Keratoconus; Ectasia; Degeneration
Interventions: Drug: Ciprofloxicine or Vigamox or other.; Drug: Nonsteroidal (Acular, Voltaren Xibrom, etc); Drug: Steroid (FML, Pred Forte, Flarex, etc.)
Sponsors: Innovative Medical; Innovative Medical
Recruiting - verified February 2012 - Condition: Idiopathic Intracranial Hypertension
Interventions: Drug: Acetazolamide; Drug: Placebo; Behavioral: Formal weight loss counselling program
Sponsors: St. Luke's-Roosevelt Hospital Center; St. Luke's-Roosevelt Hospital Center; National Eye Institute (NEI); University of Rochester; University of Iowa; University of California, Davis
Recruiting - verified May 2012 - Condition: Leukemia
Interventions: Drug: cyclophosphamide; Drug: cytarabine; Drug: dexamethasone; Drug: doxorubicin hydrochloride; Drug: imatinib mesylate; Drug: methotrexate; Drug: methylprednisolone; Drug: pegaspargase; Drug: vincristine sulfate; Other: pharmacological study
Sponsors: OHSU Knight Cancer Institute; OHSU Knight Cancer Institute; National Cancer Institute (NCI)
Recruiting - verified March 2011 - Condition: Fever
Interventions: Drug: ibuprofen; Drug: acetaminophen
Sponsors: Cumberland Pharmaceuticals; Cumberland Pharmaceuticals
Recruiting - verified March 2012 - Condition: Multiple Sclerosis
Intervention: Dietary Supplement: Lipoic Acid
Sponsors: Portland VA Medical Center; Portland VA Medical Center; Oregon Health and Science University
Recruiting - verified January 2012 - Condition: Multiple Myeloma
Interventions: Drug: Perifosine; Drug: Perifosine Placebo; Drug: Bortezomib; Drug: Dexamethasone
Sponsors: AEterna Zentaris; AEterna Zentaris; Dana-Farber Cancer Institute
Recruiting - verified February 2012 - Condition: Leukemia-Lymphoma, Adult T-Cell
Intervention: Drug: Etoposide, Vincristine, Doxorubicin, Prednisone, Cyclophosphamide (EPOCH) with Bortezomib and Raltegravir
Sponsors: Washington University School of Medicine; Washington University School of Medicine
Recruiting - verified May 2012 - Conditions: Acute Respiratory Distress Syndrome (ARDS); Lung Injury, Acute; Acute Lung Injury (ALI)
Interventions: Drug: SB-681323 Intravenous 3mg; Drug: SB-681323 Intravenous 7.5 mg; Drug: SB-681323 Intravenous 7.5mg; Drug: SB-681323 Intravenous 10mg; Other: Placebo
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified July 2011 - Condition: Ocular Myasthenia Gravis
Interventions: Drug: Prednisone; Drug: Placebo
Sponsors: University of Miami; Michael Benatar; Food and Drug Administration (FDA)
Recruiting - verified February 2012 - Condition: Immune Thrombocytopenic Purpura
Interventions: Drug: Dexamethasone USP Micronized; Drug: Prednisone
Sponsors: National Heart, Lung, and Blood Institute (NHLBI); National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified July 2011 - Condition: Multiple Myeloma
Intervention: Drug: IMGN901
Sponsors: ImmunoGen, Inc.; ImmunoGen, Inc.
Recruiting - verified October 2011 - Condition: Legg-Calve Perthes Disease
Intervention: Drug: Aristospan 20mg
Sponsors: Seattle Children's Hospital; Seattle Children's Hospital
Recruiting - verified June 2011 - Condition: Polycystic Ovary Syndrome
Interventions: Radiation: 3-D Ultrasound; Drug: hCG with and without FSH; Drug: Adrenocorticotropin (ACTH) infusion; Drug: Diazoxide and hCG
Sponsors: University of California, San Diego; University of California, San Diego
Recruiting - verified August 2011 - Condition: Glaucoma
Interventions: Drug: Prednisolone 1%; Drug: Diclofenac 0.1%; Drug: Artificial Tears
Sponsors: University of Miami; University of Miami; Bascom Palmer Eye Institute; University of Pittsburgh
Recruiting - verified August 2011 - Condition: Familial Adenomatous Polyposis
Interventions: Drug: eflornithine (DFMO); Drug: acetylsalicylic acid (aspirin); Other: placebo; Other: laboratory biomarker analysis; Other: gene expression analysis; Other: telephone-based intervention; Other: immunohistochemistry staining method; Other: reverse transcriptase-polymerase chain reaction; Other: protein expression analysis
Sponsors: Mayo Clinic; Mayo Clinic
Recruiting - verified March 2012 - Condition: Acute Lymphoblastic Leukemia
Interventions: Drug: Prednisone; Drug: Vincristine; Drug: Doxorubicin; Drug: PEG-asparaginase; Drug: Cytarabine; Drug: Methotrexate; Drug: Imatinib; Drug: Clofarabine; Drug: 6 Mercaptopurine
Sponsors: Massachusetts General Hospital; Massachusetts General Hospital; Dana-Farber Cancer Institute; Beth Israel Deaconess Medical Center; Enzon Pharmaceuticals, Inc.; Genzyme
Recruiting - verified April 2012 - Condition: Lymphoma
Interventions: Biological: rituximab; Drug: cyclophosphamide; Drug: doxorubicin hydrochloride; Drug: prednisone; Drug: vincristine sulfate; Drug: vorinostat; Other: R-CHOP regimen; Other: laboratory biomarker analysis
Sponsors: National Cancer Institute (NCI); Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified July 2011 - Condition: Cutaneous T-cell Lymphoma
Interventions: Drug: Curcumin (Turmeric); Behavioral: Questionnaires; Other: Photos
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Not yet recruiting - verified May 2012 - Conditions: Leukemia; Acute Lymphocytic Leukemia
Interventions: Drug: Everolimus (RAD001); Drug: Cyclophosphamide; Drug: Vincristine; Drug: Doxorubicin; Drug: Dexamethasone; Drug: Mesna; Drug: Methotrexate; Drug: Ara-C (Cytarabine); Drug: Solu-Medrol; Drug: G-CSF
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Novartis
Recruiting - verified November 2011 - Condition: Hemangioma of Infancy
Interventions: Drug: propranolol; Drug: Prednisolone
Sponsors: Children's Research Institute; Children's Research Institute
Recruiting - verified October 2011 - Condition: Mouth Neoplasms
Interventions: Drug: 1,25-dihydroxyvitamin D3; Drug: celecoxib; Drug: 1,25-dihydroxyvitamin D3 + celecoxib
Sponsors: Department of Veterans Affairs; Department of Veterans Affairs
Recruiting - verified March 2012 - Condition: Type 1 Diabetes Mellitus
Intervention: Drug: Rilonacept
Sponsors: University of Texas Southwestern Medical Center; University of Texas Southwestern Medical Center
Recruiting - verified December 2010 - Condition: Nasopharyngeal Carcinoma
Interventions: Drug: Docetaxel; Drug: Carboplatin; Drug: Dexamethasone; Drug: EBV-specific cytotoxic T lymphocytes
Sponsors: Baylor College of Medicine; Baylor College of Medicine; Texas Children's Hospital; The Methodist Hospital System; Center for Cell and Gene Therapy, Baylor College of Medicine; M.D. Anderson Cancer Center
Recruiting - verified April 2012 - Conditions: Stenosing Tenosynovitis; Trigger Finger
Interventions: Drug: One cortisone injection; Drug: Two cortisone Injections
Sponsors: Rothman Institute Orthopaedics; Rothman Institute Orthopaedics
Recruiting - verified November 2011 - Condition: Metastatic Prostate Cancer
Interventions: Drug: Bevacizumab; Drug: Lenalidomide; Drug: Docetaxel; Drug: Prednisone
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified January 2012 - Conditions: Leukemia; Acute Lymphoblastic Leukemia
Intervention: Drug: Dasatinib, Mitoxantrone, Cytarabine
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center; Bristol-Myers Squibb
Recruiting - verified January 2012 - Condition: Multiple Myeloma
Intervention: Drug: Vorinostat, Lenalidomide, Bortezomib, Dexamethasone
Sponsors: Emory University; Emory University; Merck; Celgene Corporation
Recruiting - verified April 2012 - Condition: Kidney Transplant
Interventions: Drug: Tacrolimus; Drug: Sirolimus (Rapamune, Rapamycin); Drug: Mycophenolate Mofetil + Prednisone
Sponsors: Mayo Clinic; Mayo Clinic; Wyeth is now a wholly owned subsidiary of Pfizer
Recruiting - verified December 2011 - Condition: Psoriasis
Interventions: Drug: Methotrexate; Drug: Adalimumab (Humira)
Sponsors: Tufts Medical Center; Tufts Medical Center; Abbott
Recruiting - verified July 2011 - Conditions: Graft Versus Host Disease; Recurrent Adult Acute Lymphoblastic Leukemia
Interventions: Drug: prednisone; Drug: methylprednisolone; Other: questionnaire administration
Sponsors: Fred Hutchinson Cancer Research Center; Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium; National Cancer Institute (NCI)
Recruiting - verified February 2012 - Condition: Migraine Headache
Interventions: Drug: bupivicaine/methylprednisolone (Active Injection); Drug: Placebo Injection
Sponsors: Mayo Clinic; Mayo Clinic
Recruiting - verified November 2011 - Condition: Pulmonary Nodule
Interventions: Drug: dexamethasone; Procedure: computed tomography; Radiation: fludeoxyglucose F 18
Sponsors: Barbara Ann Karmanos Cancer Institute; Barbara Ann Karmanos Cancer Institute; National Cancer Institute (NCI)
Recruiting - verified November 2011 - Condition: Leukemia, Lymphocytic, Acute
Interventions: Drug: Methotrexate; Drug: Vincristine; Drug: PEG-l-asparaginase; Drug: Dexamethasone; Drug: Rituximab
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified March 2012 - Condition: Migraine With Aura
Interventions: Drug: sumatriptan with naprosyn; Drug: placebo
Sponsors: Dent Neurologic Institute; Dent Neurologic Institute
Recruiting - verified February 2012 - Conditions: Chronic Kidney Disease; Cardiovascular Disease
Intervention: Drug: ANAKINRA (IL-1ra)
Sponsors: Department of Veterans Affairs; Department of Veterans Affairs
Not yet recruiting - verified March 2012 - Conditions: Leukemia; Amyloidosis
Interventions: Drug: Lenalidomide; Drug: Melphalan; Drug: Dexamethasone
Sponsors: Stanford University; Stanford University; Celgene Corporation
Recruiting - verified May 2012 - Condition: Diabetes Mellitus, Type I
Interventions: Biological: Purified Pancreatic Islets; Drug: Etanercept
Sponsors: Massachusetts General Hospital; Massachusetts General Hospital
Recruiting - verified January 2012 - Condition: Advanced Cancer, Various, NOS
Interventions: Drug: BMS-833923; Drug: Lenalidomide; Drug: Dexamethasone; Drug: Bortezomib
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb; Exelixis
Recruiting - verified February 2012 - Conditions: Leukemia; Lymphoma
Interventions: Drug: cytarabine; Drug: decitabine; Drug: doxorubicin hydrochloride; Drug: imatinib mesylate; Drug: methotrexate; Drug: pegaspargase; Drug: prednisone; Drug: vincristine sulfate; Drug: vorinostat
Sponsors: Masonic Cancer Center, University of Minnesota; Masonic Cancer Center, University of Minnesota
Recruiting - verified December 2011 - Condition: Lymphoma, Non-Hodgkin
Interventions: Procedure: Autologous Transplant; Procedure: Allogeneic Transplant
Sponsors: Washington University School of Medicine; Washington University School of Medicine
Recruiting - verified September 2011 - Condition: Healthy
Intervention:
Sponsors: University of Nebraska; University of Nebraska
Recruiting - verified August 2011 - Condition: Migraine Headache
Interventions: Drug: Treximet (Imitrex + naproxen sodium); Other: Inert Placebo
Sponsors: University of Toledo Health Science Campus; University of Toledo Health Science Campus; GlaxoSmithKline
Recruiting - verified January 2012 - Conditions: Leukemia, Myeloid, Acute; Leukemia, Lymphoblastic, Acute; Leukemia, Myelocytic, Chronic
Interventions: Other: Allogeneic Lymphocytes; Drug: Fludarabine; Drug: Cyclophosphamide; Drug: Methylprednisolone; Drug: Cyclosporine
Sponsors: National Institutes of Health Clinical Center (CC); National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified November 2011 - Condition: Leprosy
Intervention: Drug: clofazamine
Sponsors: Kaiser Permanente; Kaiser Permanente; National Hansen's Disease Program
Available - verified April 2012 - Conditions: Mucocutaneous Lymph Node Syndrome; Kawasaki Disease
Interventions: Drug: Etanercept; Drug: Placebo
Sponsors: Seattle Children's Hospital; Michael Portman; FDA Office of Orphan Products Development; Amgen
Recruiting - verified April 2012 - Conditions: Chronic Sinusitis; Rhinosinusitis; Nasal Polyps
Intervention: Drug: Prednisone
Sponsors: Northwestern University; Northwestern University; National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified November 2011 - Conditions: Psoriasis; Melanoma; Non-melanoma Skin Cancer
Intervention: Drug: etanercept
Sponsors: University of Alabama at Birmingham; University of Alabama at Birmingham; Amgen
Recruiting - verified August 2011 - Condition: Rheumatoid Arthritis
Interventions: Drug: Etanercept; Drug: Adalimumab
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified May 2012 - Conditions: Non-hodgkins Lymphoma; Hodgkins Lymphoma; Multiple Myeloma
Intervention: Drug: Oncaspar, Doxil, Decadron
Sponsors: Penn State University; Penn State University
Recruiting - verified May 2012 - Condition: Diffuse Large B-cell Lymphoma
Interventions: Drug: RICE; Drug: GaRD Treatment
Sponsors: Loyola University; Loyola University; Genta Incorporated
Recruiting - verified September 2011 - Condition: Chronic Obstructive Pulmonary Disease (COPD)
Intervention: Drug: Beclomethasone
Sponsors: Weill Medical College of Cornell University; Weill Medical College of Cornell University
Recruiting - verified August 2011 - Condition: Lymphoma
Interventions: Biological: bleomycin sulfate; Biological: filgrastim; Drug: ABVD regimen; Drug: BEACOPP regimen; Drug: cyclophosphamide; Drug: dacarbazine; Drug: doxorubicin hydrochloride; Drug: etoposide; Drug: prednisone; Drug: procarbazine hydrochloride; Drug: vinblastine sulfate; Drug: vincristine sulfate; Radiation: fludeoxyglucose F 18
Sponsors: National Cancer Institute (NCI); Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified January 2012 - Condition: HIV Infections
Interventions: Drug: Chloroquine; Drug: Placebo
Sponsors: AIDS Clinical Trials Group; AIDS Clinical Trials Group; National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified February 2012 - Conditions: Multiple Myeloma; Plasma Cell Leukemia
Interventions: Drug: ARRY-520, KSP(Eg5) inhibitor; intravenous; Drug: Filgrastim, granulocyte-colony stimulating factor (G-CSF); subcutaneous; Drug: Dexamethasone, steroid; oral
Sponsors: Array BioPharma; Array BioPharma
Recruiting - verified February 2012 - Measurement of Pituitary Volume and Hormonal Changes in Patients With Post-traumatic Stress DisorderCondition: Posttraumatic Stress Disorder
Interventions: Procedure: MRI of the pituitary; Procedure: DEX/CRH test
Sponsors: Cedars-Sinai Medical Center; Cedars-Sinai Medical Center
Recruiting - verified December 2008 - Condition: Focal Segmental Glomerulosclerosis
Interventions: Drug: Adalimumab; Drug: Lisinopril, losartan, and atorvastatin; Drug: galactose
Sponsors: New York University School of Medicine; New York University School of Medicine; University of Michigan; The Cleveland Clinic; National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Recruiting - verified April 2012 - Condition: Arthritis, Juvenile Rheumatoid
Interventions: Drug: Celecoxib; Drug: Naproxen
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2012 - Condition: Multiple Myeloma
Interventions: Procedure: Stem cell transplant x 1 or x 2; Drug: lenalidomide and dexamethasone
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center; Tufts Medical Center; Lahey Clinic
Recruiting - verified January 2012 - Condition: Chronic Plaque Psoriasis
Intervention: Biological: HUMIRA® (adalimumab)
Sponsors: Abbott; Abbott
Recruiting - verified January 2012 - Condition: Leukemia
Interventions: Biological: filgrastim; Biological: graft versus host disease prophylaxis/therapy; Drug: cyclophosphamide; Drug: cytarabine; Drug: dasatinib; Drug: dexamethasone; Drug: doxorubicin hydrochloride; Drug: etoposide; Drug: leucovorin calcium; Drug: methotrexate; Drug: methylprednisolone; Drug: prednisone; Drug: vincristine sulfate; Genetic: cytogenetic analysis; Genetic: polymerase chain reaction; Other: flow cytometry; Procedure: allogeneic hematopoietic stem cell transplantation; Procedure: peripheral blood stem cell transplantation; Radiation: total-body irradiation
Sponsors: National Cancer Institute (NCI); Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Conditions: Multiple Myeloma; Plasma Cell Neoplasm
Interventions: Drug: Lenalidomide & Dexamethasone; Drug: Lenalidomide & Dexamethasone; Drug: Lenalidomide & Dexamethasone
Sponsors: PrECOG, LLC.; PrECOG, LLC.; Celgene Corporation
Recruiting - verified April 2012 - Condition: Lymphoma
Interventions: Drug: Zolinza (vorinostat); Drug: Cyclophosphamide; Drug: Doxorubicin; Drug: Vincristine; Drug: Prednisone
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Merck
Recruiting - verified April 2012 - Condition: Lymphoma
Interventions: Biological: rituximab; Drug: cyclophosphamide; Drug: dexamethasone; Drug: lenalidomide
Sponsors: Mayo Clinic; Mayo Clinic; National Cancer Institute (NCI)
Recruiting - verified April 2012 - Condition: Juvenile Idiopathic Arthritis
Interventions: Biological: adalimumab; Drug: Methotrexate
Sponsors: Abbott; Abbott
Recruiting - verified April 2012 - Condition: Multiple Myeloma
Interventions: Drug: Lenalidomide; Drug: Dexamethasone
Sponsors: University of Pittsburgh; University of Pittsburgh
Recruiting - verified May 2012 - Conditions: Lupus Nephritis; Lupus Erythematosus, Systemic
Interventions: Drug: Abatacept; Drug: cyclophosphamide; Drug: azathioprine; Drug: prednisone; Drug: abatacept placebo; Drug: azathioprine placebo
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); National Institute of Allergy and Infectious Diseases (NIAID); Immune Tolerance Network (ITN)
Recruiting - verified November 2011 - Conditions: Macular Edema; Retinal Vein Occlusion
Interventions: Drug: Fluocinolone Acetonide; Drug: Fluocinolone Acetonide
Sponsors: Alimera Sciences; Alimera Sciences
Recruiting - verified January 2012 - Condition: Brain Neoplasms
Intervention: Drug: Ferumoxytol
Sponsors: OHSU Knight Cancer Institute; OHSU Knight Cancer Institute; National Cancer Institute (NCI); AMAG Pharmaceuticals, Inc.
Recruiting - verified March 2012 - Condition: Cystic Fibrosis
Interventions: Drug: digitoxin; Drug: digitoxin; Other: placebo
Sponsors: Johns Hopkins University; Pamela L. Zeitlin, MD, PhD; FDA Office of Orphan Products Development
Recruiting - verified May 2012 - Condition: Multiple Myeloma
Interventions: Drug: M-VTD-PACE; Drug: TT3-LITE Regimen (L-TT3)
Sponsors: University of Arkansas; University of Arkansas; Millennium Pharmaceuticals, Inc.
Recruiting - verified April 2012 - Condition: Bronchitis
Intervention: Drug: Etanercept inhibition of ozone-induced airway hyper-responsiveness.
Sponsors: National Institute of Environmental Health Sciences (NIEHS); National Institute of Environmental Health Sciences (NIEHS)
Recruiting - verified August 2009 - Condition: Patent Ductus Arteriosus
Interventions: Other: feeding; Other: fasting
Sponsors: University of California, San Francisco; University of California, San Francisco
Recruiting - verified April 2012 - Condition: Acute Graft Versus Host Disease
Intervention: Drug: Etanercept (Enbrel)
Sponsors: University of Michigan Cancer Center; University of Michigan Cancer Center
Recruiting - verified September 2011 - Condition: Autoimmune Disorder
Interventions: Biological: anti-thymocyte globulin; Drug: carmustine; Drug: cytarabine; Drug: etoposide; Drug: melphalan; Drug: prednisone; Procedure: autologous hematopoietic stem cell transplantation; Procedure: peripheral blood stem cell transplantation; Procedure: syngeneic bone marrow transplantation; Other: laboratory biomarker analysis
Sponsors: Fred Hutchinson Cancer Research Center; Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium; National Cancer Institute (NCI)
Recruiting - verified January 2012 - Condition: Thrombotic Thrombocytopenic Purpura
Interventions: Drug: Cyclosporine; Drug: Prednisone
Sponsors: Ohio State University; Ohio State University
Recruiting - verified March 2012 - Condition: Lymphoma
Interventions: Biological: rituximab; Drug: bortezomib; Drug: cyclophosphamide; Drug: dexamethasone; Other: questionnaire administration; Procedure: quality-of-life assessment
Sponsors: Mayo Clinic; Mayo Clinic; National Cancer Institute (NCI)
Recruiting - verified March 2012 - Condition: Asthma
Intervention: Drug: salmeterol
Sponsors: Nemours Children's Clinic; Nemours Children's Clinic; University of Florida
Recruiting - verified August 2011 - Condition: Age-Related Macular Degeneration
Interventions: Drug: Fluocinolone Acetonide; Drug: Fluocinolone Acetonide; Drug: Sham Injection
Sponsors: Alimera Sciences; Alimera Sciences
Recruiting - verified January 2012 - Condition: Oral Chronic Graft-versus-host Disease
Interventions: Drug: Tacrolimus; Drug: Dexamethasone
Sponsors: Dana-Farber Cancer Institute; Brigham and Women's Hospital; Dana-Farber Cancer Institute; Children's Hospital Boston; Beth Israel Deaconess Medical Center; Massachusetts General Hospital
Recruiting - verified February 2011 - Condition: Type 1 Diabetes Mellitus
Intervention: Drug: Islets of Langerhans transplantation
Sponsors: University of Illinois; University of Illinois
Recruiting - verified August 2011 - Condition: Psoriasis
Interventions: Procedure: Narrow band (310-312 nm) ultraviolet light B phototherapy; Drug: etanercept
Sponsors: University of California, San Francisco; University of California, San Francisco
Recruiting - verified February 2012 - Condition: Multiple Myeloma and Plasma Cell Neoplasm
Interventions: Drug: dexamethasone; Drug: lenalidomide; Drug: melphalan
Sponsors: Boston Medical Center; Boston Medical Center
Recruiting - verified February 2012 - Condition: Cardiac Arrest
Interventions: Drug: Normal Saline; Drug: Hydrocortisone
Sponsors: Beth Israel Deaconess Medical Center; Beth Israel Deaconess Medical Center; American Heart Association
Recruiting - verified July 2011 - Condition: Lymphoma
Interventions: Biological: pegfilgrastim; Biological: rituximab; Drug: cyclophosphamide; Drug: doxorubicin hydrochloride; Drug: lenalidomide; Drug: prednisone; Drug: vincristine sulfate; Genetic: polymorphism analysis; Other: laboratory biomarker analysis
Sponsors: Mayo Clinic; Mayo Clinic; National Cancer Institute (NCI)
Recruiting - verified April 2012 - Conditions: Leukemia; Acute Lymphoblastic Leukemia
Interventions: Drug: Rituximab; Drug: Cyclophosphamide (CTX); Drug: Doxorubicin; Drug: Vincristine; Drug: Dexamethasone; Drug: Methotrexate (MTX); Drug: Cytarabine; Drug: G-CSF; Drug: Mesna; Drug: Pegylated asparaginase; Drug: Pegfilgrastim; Drug: Solumedrol
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified April 2012 - Conditions: Burkitt's Lymphoma; Burkitt'S-like Lymphoma
Interventions: Drug: Rituximab; Drug: Cyclophosphamide; Drug: Doxorubicin; Drug: Vincristine; Drug: Dexamethasone; Drug: G-CSF; Drug: Cytarabine; Drug: Methotrexate
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified December 2011 - Condition: Sciatica
Interventions: Drug: Prednisone; Drug: Placebo
Sponsors: Kaiser Permanente; Kaiser Permanente; National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Recruiting - verified May 2012 - Condition: Ulcerative Colitis
Intervention: Drug: mesalamine
Sponsors: University of Pennsylvania; University of Pennsylvania; National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); Shire Development LLC
Recruiting - verified December 2011 - Condition: Pulmonary Fibrosis
Interventions: Drug: N-acetylcysteine (NAC); Drug: Placebo
Sponsors: National Heart, Lung, and Blood Institute (NHLBI); National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified January 2012 - Condition: Multiple Myeloma and Plasma Cell Neoplasm
Interventions: Drug: bortezomib; Drug: dexamethasone; Drug: lenalidomide
Sponsors: National Cancer Institute (NCI); Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified June 2011 - Condition: Familial Adenomatous Polyposis
Interventions: Dietary Supplement: curcumin; Drug: placebo
Sponsors: Johns Hopkins University; Johns Hopkins University
Recruiting - verified March 2012 - Condition: Graft Versus Host Disease
Interventions: Procedure: stem cell transplant; Drug: tacrolimus (standard GVHD prophylaxis); Drug: mycophenolate (standard GVHD prophylaxis); Drug: etanercept; Drug: methoxsalen
Sponsors: University of Michigan Cancer Center; University of Michigan Cancer Center; Therakos; Amgen
Recruiting - verified November 2011 - Condition: Leukemia
Interventions: Biological: sargramostim; Drug: busulfan; Drug: cyclophosphamide; Drug: dexamethasone; Drug: etoposide; Procedure: autologous bone marrow transplantation; Procedure: autologous hematopoietic stem cell transplantation; Procedure: peripheral blood stem cell transplantation; Radiation: total-body irradiation; Procedure: Bone marrow aspiration and biopsy; Procedure: Apheresis
Sponsors: Masonic Cancer Center, University of Minnesota; Masonic Cancer Center, University of Minnesota
Recruiting - verified January 2012 - Condition: Fanconi Anemia
Interventions: Biological: anti-thymocyte globulin; Drug: cyclophosphamide; Drug: fludarabine phosphate; Procedure: hematopoietic stem cell transplantation; Drug: methylprednisolone; Drug: filgrastim; Drug: cyclosporine; Drug: Mycophenolate Mofetil
Sponsors: Masonic Cancer Center, University of Minnesota; Masonic Cancer Center, University of Minnesota
Recruiting - verified December 2011 - Conditions: Neutropenia; Infection
Interventions: Drug: Standard antimicrobial therapy; Biological: Granulocyte transfusions; Drug: G-CFS/dexamethasone; Device: Apheresis machine
Sponsors: National Heart, Lung, and Blood Institute (NHLBI); National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified July 2011 - Condition: Brain Cancer
Intervention: Drug: Palonosetron (Aloxi) and Dexamethasone
Sponsors: Duke University; Duke University; Eisai Inc.; National Institute of Neurological Disorders and Stroke (NINDS)
Recruiting - verified March 2012 - Condition: Hepatic Veno-Occlusive Disease
Intervention: Drug: Defibrotide
Sponsors: Gentium SpA; Gentium SpA
Recruiting - verified May 2012 - Conditions: Coronary Artery Disease; Overweight
Interventions: Drug: Salsalate; Drug: Placebo
Sponsors: Joslin Diabetes Center; Allison Goldfine; Beth Israel Deaconess Medical Center; Tufts Medical Center
Recruiting - verified March 2012 - Conditions: Lymphoma, B-Cell; Follicular Lymphoma
Intervention: Drug: rituximab, cyclophosphamide, doxorubicin, vincristine, bortezomib, prednisone
Sponsors: Emory University; Emory University; Millennium Pharmaceuticals, Inc.
Recruiting - verified March 2012 - Condition: Graft Versus Host Disease
Interventions: Procedure: Photopheresis; Drug: Methylprednisolone
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified March 2012 - Conditions: Crohn's Disease; Ulcerative Colitis; Inflammatory Bowel Diseases
Interventions: Drug: conventional systemic agents; Biological: infliximab; Biological: Biological therapies other than infliximab
Sponsors: Centocor Ortho Biotech Services, L.L.C.; Centocor Ortho Biotech Services, L.L.C.
Recruiting - verified May 2012 - Condition: Lymphoma
Interventions: Biological: rituximab; Drug: bortezomib; Drug: carboplatin; Drug: dexamethasone; Drug: etoposide; Drug: ifosfamide; Genetic: polymerase chain reaction; Genetic: western blotting
Sponsors: AIDS Malignancy Clinical Trials Consortium; AIDS Malignancy Clinical Trials Consortium; National Cancer Institute (NCI)
Recruiting - verified December 2011 - Condition: Shoulder Pain
Interventions: Drug: Lidocaine; Drug: Triamcinolone + Lidocaine; Drug: Triamcinolone + Lidocaine; Drug: Triamcinolone + Lidocaine
Sponsors: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Recruiting - verified December 2011 - Condition: Adenomatous Polyposis Coli
Interventions: Drug: Celecoxib; Drug: Placebo
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2012 - Condition: Colorectal Cancer
Intervention: Drug: Aspirin
Sponsors: University of California, Irvine; University of California, Irvine
Recruiting - verified March 2012 - Condition: Asthma
Interventions: Drug: budesonide/formoterol or fluticasone/salmeterol; Drug: budesonide/formoterol or fluticasone/salmeterol
Sponsors: Gelb, Arthur F., M.D.; Gelb, Arthur F., M.D.
Recruiting - verified March 2012 - Condition: Recurrent Respiratory Papillomatosis
Interventions: Drug: celebrex (celecoxib); Drug: placebo capsules
Sponsors: North Shore Long Island Jewish Health System; North Shore Long Island Jewish Health System; National Institute on Deafness and Other Communication Disorders (NIDCD)
Recruiting - verified January 2012 - Condition: Atopic Dermatitis
Intervention: Drug: Pimecrolimus
Sponsors: Valeant Pharmaceuticals International, Inc.; Valeant Pharmaceuticals International, Inc.; Clinical Research Computing Unit (University of Pennsylvania)
Recruiting - verified May 2012 - Condition: Leukemia
Interventions: Drug: cyclophosphamide; Drug: cytarabine; Drug: daunorubicin hydrochloride; Drug: dexamethasone; Drug: doxorubicin hydrochloride; Drug: mercaptopurine; Drug: methotrexate; Drug: pegaspargase; Drug: thioguanine; Drug: vincristine sulfate; Radiation: radiation therapy
Sponsors: National Cancer Institute (NCI); Cancer and Leukemia Group B; National Cancer Institute (NCI); Eastern Cooperative Oncology Group; Southwest Oncology Group
Recruiting - verified May 2012 - Condition: Leukemia
Interventions: Drug: asparaginase; Drug: cyclophosphamide; Drug: cytarabine; Drug: daunorubicin hydrochloride; Drug: dexamethasone; Drug: etoposide; Drug: lestaurtinib; Drug: leucovorin calcium; Drug: mercaptopurine; Drug: methotrexate; Drug: methylprednisolone; Drug: pegaspargase; Drug: prednisone; Drug: therapeutic hydrocortisone; Drug: vincristine sulfate
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Condition: Multiple Myeloma
Interventions: Drug: Bortezomib; Drug: Dexamethasone; Drug: PD 0332991
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2012 - Condition: Acute Lymphoblastic Leukemia
Interventions: Drug: Prednisone, Vincristine, Daunorubicin, PEG-L-asparaginase, Erwinia L-asparaginase, Doxorubicin, Cyclophosphamide, Cytarabine, Thioguanine; Drug: Clofarabine, Methotrexate, Mercaptopurine, Dexamethasone, Etoposide, Dasatinib
Sponsors: St. Jude Children's Research Hospital; St. Jude Children's Research Hospital; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Condition: Breast Cancer
Intervention:
Sponsors: Beth Israel Deaconess Medical Center; Beth Israel Deaconess Medical Center
Recruiting - verified February 2012 - Condition: Multiple Myeloma
Interventions: Drug: lenalidomide (Revlimid®); Drug: Cyclophosphamide; Drug: Prednisone
Sponsors: Indiana University; Indiana University School of Medicine; Celgene Corporation
Recruiting - verified November 2011 - Condition: Prostate Cancer
Interventions: Dietary Supplement: calcitriol; Drug: ketoconazole; Drug: therapeutic hydrocortisone
Sponsors: Roswell Park Cancer Institute; Roswell Park Cancer Institute; Department of Defense
Recruiting - verified January 2012 - Condition: Lung Cancer
Interventions: Drug: celecoxib; Drug: Docetaxel; Drug: pemetrexed disodium; Other: laboratory biomarker analysis
Sponsors: Vanderbilt-Ingram Cancer Center; Vanderbilt-Ingram Cancer Center; National Cancer Institute (NCI)
Recruiting - verified October 2011 - Conditions: Myelodysplastic Syndrome; Hodgkin's Lymphoma; Non-Hodgkin's Disease; Acute Leukemia; Multiple Myeloma
Interventions: Drug: Cyclophosphamide; Biological: rituximab; Drug: Methotrexate; Drug: Sirolimus; Drug: Cyclosporine; Drug: Doxorubicin hydrochloride; Drug: Etoposide; Drug: Fludarabine phosphate; Drug: Prednisone; Drug: Vincristine sulfate; Drug: Cytarabine; Drug: Tacrolimus; Biological: Alemtuzumab
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified June 2011 - Conditions: Psoriasis; Arthritis, Psoriatic
Interventions: Biological: ustekinumab; Biological: Biological therapies other than infliximab and ustekinumab; Drug: conventional systemic agents; Biological: infliximab
Sponsors: Centocor Ortho Biotech Services, L.L.C.; Centocor Ortho Biotech Services, L.L.C.
Recruiting - verified May 2012 - Conditions: Prostate Cancer; Pain
Interventions: Drug: Azacitidine; Drug: Docetaxel; Drug: Prednisone; Genetic: Azacitidine induced demethylation of repetitive elements.; Genetic: GADD45α methylation and expression in prostate cancer tissue; Genetic: GADD45α methylation in serum DNA
Sponsors: University of Miami Sylvester Comprehensive Cancer Center; University of Miami Sylvester Comprehensive Cancer Center
Recruiting - verified March 2012 - Conditions: Leukemia; Lymphoblastic Lymphoma; Leukemia, Lymphoblastic, Acute
Interventions: Drug: Doxorubicin; Drug: Cyclophosphamide; Drug: Cytarabine; Drug: Dexamethasone; Drug: Methotrexate; Drug: Vincristine; Drug: Nelarabine
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified February 2012 - Condition: Obstetric Labor, Premature
Intervention: Drug: Indomethacin and Nifedipine
Sponsors: Stanford University; Stanford University
Recruiting - verified June 2011 - Condition: Multiple Myeloma and Plasma Cell Neoplasm
Interventions: Biological: filgrastim; Drug: dexamethasone; Drug: melphalan; Procedure: autologous hematopoietic stem cell transplantation
Sponsors: Mayo Clinic; Mayo Clinic; National Cancer Institute (NCI)
Recruiting - verified January 2012 - Conditions: Psoriasis; Metabolic Syndrome; Hyperlipidemia; Obesity; Hypertension
Intervention: Drug: Etanercept
Sponsors: Massachusetts General Hospital; Massachusetts General Hospital; Amgen
Recruiting - verified February 2012 - Condition: Acute Lymphoblastic Leukemia
Interventions: Drug: Doxorubicin; Drug: Cytarabine; Drug: Methotrexate; Drug: Vincristine; Drug: Cyclophosphamide; Drug: Methylprednisone; Drug: Hydrocortisone Sodium Succinate; Drug: Dexamethasone; Drug: 6-MP; Drug: PEG-Asparaginase; Drug: Imatinib; Drug: Etoposide; Procedure: Radiation Therapy; Drug: E. coli Asparaginase
Sponsors: Dana-Farber Cancer Institute; Dana-Farber Cancer Institute; Massachusetts General Hospital; Children's Hospital Boston
Recruiting - verified August 2011 - Condition: Psoriasis
Interventions: Drug: Imiquimod; Drug: Clobetasol (glucosteroid); Device: Excimer laser (UVB light) treatment
Sponsors: Department of Veterans Affairs; Department of Veterans Affairs; University Hospital Case Medical Center
Recruiting - verified February 2012 - Conditions: Hermansky-Pudlak Syndrome (HPS); Pulmonary Fibrosis; Oculocutaneous Albinism; Platelet Storage Pool Deficiency; Metabolic Disease
Interventions: Drug: Losartan; Drug: Zileuton; Drug: N-Acetylcysteine; Drug: Prevastatin; Drug: Erythromycin
Sponsors: National Institutes of Health Clinical Center (CC); National Human Genome Research Institute (NHGRI)
Recruiting - verified December 2010 - Condition: Multiple Sclerosis
Intervention: Drug: Aspirin
Sponsors: Mayo Clinic; Mayo Clinic; National Multiple Sclerosis Society
Recruiting - verified November 2011 - Condition: Lymphoma
Interventions: Drug: Rituximab; Drug: Cyclophosphamide; Drug: Doxorubicin; Drug: Prednisone; Drug: Vincristine; Genetic: RNA-based gene array studies; Genetic: Real time PCR gene expression studies; Genetic: Tissue-array immunohistochemical studies; Genetic: Immunoglobulin G Fc receptor genotypes determination
Sponsors: University of Miami Sylvester Comprehensive Cancer Center; University of Miami Sylvester Comprehensive Cancer Center
Recruiting - verified March 2012 - Condition: Multiple Sclerosis
Interventions: Drug: megadose oral methylprednisolone; Drug: IV methylprednisolone
Sponsors: Mount Sinai School of Medicine; Fred Lublin; National Multiple Sclerosis Society; Pfizer
Recruiting - verified April 2012 - Conditions: Leukemia; Lymphoma
Interventions: Drug: cyclophosphamide; Drug: cytarabine; Drug: dexamethasone; Drug: doxorubicin hydrochloride; Drug: leucovorin calcium; Drug: mercaptopurine; Drug: methotrexate; Drug: nelarabine; Drug: pegaspargase; Drug: prednisone; Drug: thioguanine; Drug: vincristine sulfate; Radiation: radiation therapy
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Condition: Graft vs Host Disease
Intervention: Drug: Dexamethasone 0.01% Solution
Sponsors: National Institutes of Health Clinical Center (CC); National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified July 2011 - Conditions: Acute Lymphoblastic Leukemia; Leukemia
Interventions: Drug: Cyclophosphamide; Drug: Vincristine; Drug: Doxorubicin; Drug: Dexamethasone; Drug: Dasatinib; Drug: Methotrexate; Drug: Ara-C
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Bristol-Myers Squibb
Recruiting - verified November 2011 - Condition: Leukemia
Interventions: Biological: filgrastim; Drug: asparaginase; Drug: cyclophosphamide; Drug: cytarabine; Drug: dexamethasone; Drug: doxorubicin hydrochloride; Drug: etoposide phosphate; Drug: leucovorin calcium; Drug: mercaptopurine; Drug: methotrexate; Drug: pegaspargase; Drug: prednisone; Drug: therapeutic hydrocortisone; Drug: vincristine sulfate; Radiation: radiation therapy
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified February 2012 - Condition: Fanconi Anemia
Interventions: Drug: Cyclophosphamide; Drug: Fludarabine; Drug: anti-thymocyte globulin (ATG); Procedure: Total Body Irradiation; Procedure: Bone Marrow Transplantation; Drug: Mycophenolate Mofetil; Drug: Methylprednisolone
Sponsors: Masonic Cancer Center, University of Minnesota; Masonic Cancer Center, University of Minnesota
Recruiting - verified April 2012 - Condition: Hodgkin's Lymphoma
Interventions: Drug: Adriamycin, Vinblastine, Vincristine, Bleomycin, Etoposide, Nitrogen Mustard (Cyclophosphamide), Prednisone; Procedure: Radiotherapy; Drug: Etoposide, Nitrogen Mustard (Cyclophosphamide) , Vincristine, Vinblastine, Adriamycin, Bleomycin, Prednisone
Sponsors: St. Jude Children's Research Hospital; St. Jude Children's Research Hospital
Recruiting - verified June 2011 - Conditions: Graft vs Host Disease; Blood and Marrow Transplant (BMT)
Interventions: Drug: Rituximab; Drug: Prednisone; Drug: cyclosporine A; Drug: tacrolimus
Sponsors: Stanford University; Stanford University
Recruiting - verified August 2011 - Conditions: Arthritis, Rheumatoid; Osteoarthritis
Interventions: Drug: celecoxib; Drug: Ibuprofen; Drug: Naproxen
Sponsors: Pfizer; Pfizer; The Cleveland Clinic
Recruiting - verified May 2012 - Conditions: Chronic Granulomatous Disease; Crohn'S-like IBD; Inflammatory Bowel Disease (IBD)
Intervention: Drug: Infliximab
Sponsors: National Institutes of Health Clinical Center (CC); National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified November 2011 - Condition: Precancerous Conditions
Intervention: Drug: Erlotinib & Celecoxib
Sponsors: Emory University; Emory University; National Institutes of Health (NIH)
Recruiting - verified January 2012 - Conditions: Kidney Cancer; Leukemia; Lymphoma; Multiple Myeloma and Plasma Cell Neoplasm; Myelodysplastic Syndromes
Interventions: Biological: anti-thymocyte globulin; Drug: cyclophosphamide; Drug: cyclosporine; Drug: fludarabine phosphate; Drug: mycophenolate mofetil; Procedure: stem cell transplantation; Radiation: total-body irradiation; Drug: methylprednisolone; Drug: allopurinol; Drug: filgrastim
Sponsors: Masonic Cancer Center, University of Minnesota; Masonic Cancer Center, University of Minnesota
Recruiting - verified April 2012 - Conditions: Leukoplakia, Oral; Benign Neoplasms
Interventions: Drug: sulindac; Drug: Placebo
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center; Amrita Institute of Sciences, AIMS, Cochin, India; Weill Medical College of Cornell University; Regional Cancer Center(RCC), Trivandrum, India; Narayana Hrudayalaya Hospitals
Recruiting - verified January 2012 - Condition: Myasthenia Gravis
Interventions: Procedure: thymectomy; Drug: prednisone
Sponsors: University of Alabama at Birmingham; Gary Cutter, PhD; National Institute of Neurological Disorders and Stroke (NINDS)
Recruiting - verified October 2011 - Condition: Childhood Langerhans Cell Histiocytosis
Interventions: Drug: leucovorin calcium; Drug: methotrexate; Drug: prednisolone; Drug: vinblastine sulfate
Sponsors: National Cancer Institute (NCI); Histiocyte Society
Recruiting - verified May 2007 - Conditions: Tachycardia; Chronic Orthostatic Intolerance
Interventions: Drug: Acetazolamide; Drug: Atomoxetine; Other: Baseline (No Drug); Drug: Clonidine; Drug: Entacapone; Drug: Entacapone & Propranolol; Drug: Atomoxetine & Propranolol; Drug: Indomethacin; Drug: Mecamylamine; Drug: Isosorbide Dinitrate; Dietary Supplement: Melatonin; Drug: Midodrine; Drug: Modafinil; Drug: Octreotide; Radiation: Placebo; Drug: Propranolol; Drug: Modafinil & Propranolol; Drug: Sertraline; Procedure: IV Saline; Other: Drinking Water; Device: Breathing Device; Drug: memantine; Device: Abdominal binder
Sponsors: Vanderbilt University; Satish R. Raj; National Institutes of Health (NIH)
Recruiting - verified February 2012 - Condition: Fanconi Anemia
Interventions: Biological: anti-thymocyte globulin; Biological: filgrastim; Drug: busulfan; Drug: cyclophosphamide; Drug: fludarabine phosphate; Drug: methylprednisolone; Biological: Hematopoietic stem cell transplantation
Sponsors: Masonic Cancer Center, University of Minnesota; Masonic Cancer Center, University of Minnesota
Recruiting - verified April 2012 - Condition: Multiple Sclerosis
Intervention: Biological: Hematopoietic Stem Cell Therapy
Sponsors: Northwestern University; Richard Burt, MD; Rush University Medical Center; University of Sao Paulo; Uppsala University
Recruiting - verified March 2012 - Condition: Rectal Cancer
Intervention: Drug: Oxaliplatin, Capecitabine, Celecoxib with Radiation
Sponsors: New Mexico Cancer Care Alliance; New Mexico Cancer Care Alliance
Recruiting - verified December 2011 - Condition: Coronary Arteriosclerosis
Interventions: Drug: HOE 140; Drug: Aminocaproic Acid; Drug: Placebo
Sponsors: Vanderbilt University; Vanderbilt University
Recruiting - verified July 2011 - Conditions: Autonomic Failure; Orthostatic Hypotension
Interventions: Drug: Atomoxetine; Drug: Acarbose; Drug: Pyridostigmine Bromide; Drug: Yohimbine; Drug: Midodrine HCl; Drug: placebo; Drug: Modafinil; Drug: Octreotide; Other: water intake; Drug: Diphenhydramine Hydrochloride; Drug: Ranitidine HCL; Drug: Tranylcypromine; Drug: Ergotamine/ Caffeine; Drug: Celecoxib; Drug: Pseudoephedrine; Drug: Methylphenidate; Drug: Indomethacin; Drug: Ibuprofen; Drug: Oxymetazoline 0.05% nasal solution; Dietary Supplement: Bovril; Drug: Acetazolamide; Drug: Rivastigmine tartrate; Drug: Carbidopa/levodopa; Device: abdominal binder; Device: abdominal binder (sham)
Sponsors: Vanderbilt University; Vanderbilt University
Recruiting - verified May 2012 - Condition: Hypertension
Interventions: Drug: Clonidine; Drug: Nitroglycerin transdermal; Drug: Dipyridamole/ Aspirin (Aggrenox); Drug: Desmopressin (DDAVP); Drug: Sildenafil; Drug: Nifedipine; Drug: Hydralazine; Drug: Hydrochlorothiazide; Drug: Placebo; Drug: Bosentan; Drug: Diltiazem; Drug: Eplerenone; Drug: guanfacine; Dietary Supplement: L-arginine; Drug: captopril; Drug: carbidopa; Drug: losartan; Drug: metoprolol tartrate; Drug: nebivolol hydrochloride; Drug: prazosin hydrochloride; Drug: tamsulosin hydrochloride; Other: Head-up tilt.
Sponsors: Vanderbilt University; Vanderbilt University
Recruiting - verified May 2012 - Condition: Pancreas Neoplasms
Intervention: Drug: celecoxib
Sponsors: Indiana University; Indiana University School of Medicine
Recruiting - verified March 2012 - Condition: Multiple Myeloma
Interventions: Procedure: Stem Cell Transplant; Drug: Cyclophosphamide + Mesna; Drug: Melphalan; Biological: Granulocyte-colony stimulating factor; Drug: Dexamethasone
Sponsors: Masonic Cancer Center, University of Minnesota; Masonic Cancer Center, University of Minnesota
Recruiting - verified March 2012 - Conditions: Acute Lymphoblastic Leukemia; Lymphoma, Lymphoblastic
Interventions: Drug: Etoposide, cytarabine, vincristine, dexamethasone; Drug: methotrexate, teniposide, PEG-asparaginase; Drug: mitoxantrone, cyclophosphamide, mercaptopurine, vinblastine; Drug: L-asparaginase, erwinia asparaginase; Procedure: chemotherapy, intrathecal chemotherapy, steroid therapy; Procedure: Hematopoietic Stem Cell Transplant; Procedure: Natural Killer (NK) Cell Transplant
Sponsors: St. Jude Children's Research Hospital; St. Jude Children's Research Hospital
Recruiting - verified March 2012 - Condition: Prostate Cancer
Interventions: Drug: Docetaxel; Drug: Prednisone
Sponsors: Department of Veterans Affairs; Department of Veterans Affairs; Sanofi-Aventis
Recruiting - verified September 2011 - Condition: Lung Cancer
Intervention: Drug: celecoxib
Sponsors: University of California, Los Angeles; University of California, Los Angeles; Jonsson Comprehensive Cancer Center; National Cancer Institute (NCI)
Recruiting - verified February 2012 - Conditions: Childhood Langerhans Cell Histiocytosis; Fanconi Anemia; Leukemia; Lymphoma; Myelodysplastic Syndromes; Neuroblastoma; Sarcoma; Unspecified Childhood Solid Tumor, Protocol Specific
Interventions: Biological: anti-thymocyte globulin; Drug: busulfan; Drug: cyclophosphamide; Drug: fludarabine phosphate; Drug: melphalan; Drug: methylprednisolone; Radiation: radiation therapy
Sponsors: National Cancer Institute (NCI); Milton S. Hershey Medical Center
Recruiting - verified October 2008 - Condition: Lymphoma
Interventions: Biological: rituximab; Drug: cisplatin; Drug: cytarabine; Drug: dexamethasone; Drug: gemcitabine hydrochloride; Other: clinical observation
Sponsors: NCIC Clinical Trials Group; NCIC Clinical Trials Group
Recruiting - verified May 2012
 |
Anti Inflammatory Agents Clinical Trials |
